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1. INTRODUCTION 
       Siddha system of medicine describes the healthy way of living in the world.96 
thathuvankal is the basic phenomenon and principal of siddha system of 
medicine.siddha system propounded by the siddhars. 
  Siddhars were the greatest spiritual scientists of those days.They were the 
seekers of truth. “siddhar” means  “knowledge” or “wisdom” and  “siddhi” means 
“attained of perfection”.one who had attained perfection in life is called a siddhar. 
          Siddha system of medicine deals not only cure of the disease.It also deals with 
prevention of the life from the disease and provide the ways for fulfil in life.The main 
aim of siddhars is “prevention is better than cure”.  
  The preventive principles are explained eloboratively in the text “Theraiyar 
pini anugavithi ozhukkam”. Which describes the daily and seasonal regimens to be 
followed by the people to prevent diseases.Also the sage thiruvalluvar has briefly 
explained the principles of prevention of the disease in his “Thirukkural” in 10 
couplets in the chapter “Marunthu”.The concept of “Unavae Marunthu marunthae 
unavu” is the basic paradigm followed in the system. 
“Agathiar” is known as the first physician of siddha medical science.  
Agathiar is considered to be, “Hippocrates of Siddha Medicine”  
Every system of medicine should have some fundamental principles of its own 
and such as Siddha system of Medicine too has its won doctrine theory of 
fundamental Principles based on hypothetical logic of natures law. 
This consists of 
1. Anda pinda thathuvam 
2. Panja Bootha thathuvam 
3. Tridosha thathuvam 
4. Udal thathuvam 
There are 96 kinds of thathuva’s and they constitutes the essential functions of 
the human organisms and are at once we cause and effect of our physical and mental 
well being. 
In Siddha system of medicine a close relation is maintained between man and 
Prapancham  (Universe).  Whatever changes occur in the prabanjam influences the 
human body also. 
It has been Illustrated as 
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   “n{<mk<kqz<!dt<tOk!hq{<ml<!
hq{<mk<kqz<!dt<tOk!n{<ml<!
n{<mLl<!hq{<mLl<!ye<Ox!
nxqf<Kkie<!hii<g<Gl<!OhiOk”!
. sm<mLeq!Riel<!
   According to Agathiyar Vaithiya Rathina surukam there are 4448 diseases 
commonly affecting our body, based on panchabootham and tridosha theory. 
  Eventhough so many Siddhars mentioned paediatric diseases, and treatment, 
the Agathiyar was the first to write separate literature on paediatric diseases. 
  Regarding the etiology of diseases siddhars have mentioned that, 
“Sg<gqzk<kqz<!SOvi{qkr<!gzg<Gle<X!
h,f<kqMl<!uqbikq!&e<X”!
!! ! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!!
  Which means that the influence on the health factors of a child starts since the 
early period of conception. They have also told that the physical and Mental condition 
along with the diet of mother during Pregnancy and lactation directly affects the 
child’s health and this be a causative factor of a disease. 
  That diseases attack the child from his fetal life which has been classified 
under “Karuvil Thondrum Noigal”. 
   Today's children are the future citizens of a nation.To have better nation, 
healthy citizens can contribute a lot.The health status of the children, their growth and 
development at different stages of life. 
  In siddha system of medicine,the growth and development and diseases of the 
children are explained in consonance with different stages (paruvangal).  
  Specific siddha drug formulations exclusive for pediatric usage are given by 
siddhars to combat common child hood diseases and disorders.The text book dealing 
with paediatrics in siddha system is called “Balavagadam”. 
           Akkaram is one of the agakkarana noi.Which is classified into mainly 8 
types.Ull Akkaram is one of the type of Akkaram.The disease ull Akkaram in siddha 
system due to excess heat production in moolam and affect the oral cavity to induced 
ulceration. 
  The most of signs and symptoms of the disease ull Akkaram may be correlate 
with aphthous stomatitis.The researcher has selected this disease Ull Akkaram and 
treated the effectively with the help of Poovarasu ennai. 
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2. AIM AND OBJECTIVES 
AIM: 
 The principal aim is to collect and review the ideas mentioned in ancient 
siddha literatures about the disease ULL AKKARAM and also to know the efficacy 
of the trial drug “POOVARASU ENNAI” as internal medicine from Pillaipini 
Maruthuvam, Part - I for treating this disease. The diseases ULL AKKARAM can be 
probably compared to the “APHTHOUS STOMATITIS” in modern aspect. 
 
PRIMARY OBJECTIVE: 
  An observational clinical study on an open clinical trial for the disease                    
“ULL AKKARAM”  correlated with APHTHOUS STOMATITIS responding to the 
drug “POOVARASU ENNAI” 
 
SECONDARY OBJECTIVE: 
• To collect authentic literature and review the Siddha literature about the 
disease.  
• To evaluate the disease Ull akkaram clinically by careful examination on 
etiology, clinical features, Treatment and prognosis. 
• To describe the unique diagnostic procedure mentioned in Siddha 
literature for the disease Ull akkaram. 
• To have the clinical trial in Ull akkaram while the trial medicine 
Poovarasu Ennai 
• To evaluate the Bio chemical, Pharmacological analysis and Anti 
Microbial activity of the trial medicine. 
• To study the extent of correlation of Ull akkaram explained in Siddha 
literature with aphthous stomatitis in children in modern literatures. 
• To educate the patients and their parents in terms of prevention of  
diseases, diet, habits and hygenic environment. 
• To flourish the siddha system of medicine. 
  
! !
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3. REVIEW OF LITERAURE  
SIDDHA ASPECTS 
dt<ng<gvl<< < << < << < <!
Le<Ejv<<< !
! sqX!Gpf<jkgtqe<!uib<?!dkM?!n{<{ig<G?! ge<ek<kqe<!dt<hg<gr<gt<!
Ngqb! -mr<gtqz<?! Sgikivg<! GjxU?! uibqe<! dt<hg<gl<! siqbie! Sgikiv!
hviliqh<H! -e<jl?! d{<[l<! d{Ugtqz<! liXhiMl<?! njugtqe<! d{<miGl<!
gueg<GjxU!Ohie<x!giv{r<gtiz<!H{<!d{<miujk?!ng<gvl<?!ns<svl<!we<X!
hz<OuX! ohbi<gtiz<! njpg<gh<hMgqe<xK/! ! OlZl<?! d{ju! ole<X!
d{<[r<giz<?!ke<!uibqe<!dm<hGkqgtqz<!hx<gtiz<!gchMukiZl<!d{<miGl<!
H{<{qx<Gl<!-h<ohbOv!ohiVf<Kl</!
!
OuXohbi<!)<<< Synonyms) 
 ns<svl<?!uib<Oug<giM?!uib<!Oug<gitl</!
!
-bz<<<<!
Gpf<jk!lVk<Kul<!< < << < << < < hizuigml<?!hqt<jt!hq{q!lVk<Kul<!)higl<!2*< < < < << < < < << < < < < !
! ng<gvl<?!!&zk<kqz<!gqtl<Hl<!Nuqbqe<!$M!NGl</!!-s<$M!fiuqx<G!Wxq!
nf<fiuqx<G! Oug<gim<jm!d{<mig<gq?! ! lijuh<! Ohiz<! fQX! H,k<K!Gpf<jkg<Gh<!
hz! Ke<hr<gjt! d{<mig<gq?! ! hijz! d{<{! Lcbikhc! ouXh<jh!
uqjtuqg<Gl<!-bz<Hjmb!OfibiGl</!
!
Ofib<!uVl<!upq!)< << << < Etiology) 
hqt<jt!hq{<<< q!lVk<Kul<!)higl<!2*< < << < << < < !
• Gpf<jkgTg<G!Okjubie!sk<Kg<gt<!siq!uqgqkk<kqz<!-z<zijl/!
• K~b<jlbqe<jl!
• S{<{il<H!Lkzqbux<xqe<!giv!lqGkq!
• -vsl<!Ohie<x!lVf<Kgtqe<!Oug<giM!
!!! Ngqb!giv{r<gtiz<!ubqX!ouf<K!nK!uib<!upq!outqh<hm<M!H{<j{!
Wx<hMk<Kl</!
!
hvvis!Osgvl<<<<!
• nkqg!givl<?!nkqg!d]<{Lt<t!d{Ugjt!d{<hkiZl<!
• kqeLl<!hx<gt<?!fig<G?!uib<!we<hux<jx!Sk<kl<!osb<bijlbiZl<!
Wx<hMl</!
! !
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ohiKg<GxqG{r<gt<!)< < << < << < < Clinical features) 
 “kjzbqz<!uzqBf<!kiE{<mil<!
! ! kiK!lqgUf<!Kck<K!fqx<Gl<!
! GjzBl<!ouf<K!fiouf<K!
! ! Gtqi<f<K!kiOe!uVl<hqt<jt!
! gjzBl<!ohisqB!fiouTk<Kg<!
! ! gzr<gqg<!g{<mk<!kie<!ouf<K!
! ljzbqe<!lqtG!ogitoui{<{i!
! ! uGk<Ks<!osie<Oei!lg<gvOl”!
• fiOug<giM!
• Gtqi<kz<!
• osit<T!fQI!uibqz<!-Vf<K!nkqglig!uckz<!
• fi!ouTk<K!gi{z<!
• fik<k{<{QI!Gpl<hz<!
• kjzuzqk<kz<!
• lqtgqe<!Ougk<jkBl<!kir<g!Lcbijl!
!! Ngqb!GxqG{r<gt<!ns<svk<kqe<!ohiK!GxqG{r<gtig!Gpf<jk!<<<
lVk<Kul<<< <!hiz!uigmk<kqz<!< << << < %xh<hm<Mt<te/!
OlZl<!-g<!GxqG{r<gOtiM!
• =vz<!kihqkl<!njmkz<!
• Gvz<ujt!kihqkl<!
• fiuqz<!lqtG!Ohiz<!ogih<Htl<!gi{z<!
!! Ngqb!GxqG{r<gZl<!ohiK!GxqG{r<gtig!hqt<jth<hq{q!lVk<Kul<!< < < << < < << < < <
)higl<!2*<<< !F~zqz<!%xh<hm<M!dt<tK/!
• uibqz<!H{<[{<mikz<!
• d{U!d{<{!Lcbijl!
• kjzuzq!
• ubqx<X!ohiVlz<!
• Svl<!
• gVh<hib<!out<jtbib<!hs<sqjzbib<!-vk<klib<!sQklib<!w{<o{b<!
hiz<!Ohiz!ubqX!gpqkz</!
• fiuxm<sq!
Ngqb!ohiK!GxqG{r<gt<!-Vh<hkig!hvvisOsgvk<kqz<< << << <!
%xh<hm<Mt<tK/!
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• dmz<!GtqVl<!
• kjz!uzqg<Gl<!
• kiKlqgk<!Kck<K!fqx<Gl<!
• GjzBl<?!fiUf<!oki{<jmBl<!ouf<K!H{<{iGl</!
• fiU!ouTg<Gl<!
• fisqbqz<!fQI!ucBl<!
Ngqb!ohiK!GxqG{r<gt<!-Vh<hkig!Nk<<<<lvm<silqi<kl<< < << < << < <!F~zqz<!
%xh<hm<Mt<tK/!
ng<gvl<!ujggt<!)< < << < << < < Types of Akkaram) 
 “dzgq!es<sv!Olikq!Oepkil<!
! -zG!$zqB!lqbe<x!fQkqBl<!
! nzgqz<!OsikqBl<!uQpq!G{<cBl<!
! S,zg!hizqBl<!Gliq!Bl<lOvi!
dt<ng<gvl<!
=k!zilZl<!
Yk!uiVtqz<!
OhiK!ls<svl<!
fQkq!bitOv”!
. Gpf<jk!lVk<Kul<!< < << < << < < hizuigml<!533<<< !
2/!Gpf<jk!lVk<Kul<!< < << < << < < hizuigmk<kqz<<< <!ng<gvk<kqe<!ujggt<!9!we!%xh<hm<M!
dt<tK/!!nju!
2/ $zqbg<gvl<!
3/ fQkqbg<gvl<!
4/ Osikqbg<gvl<!
5/ uQpq!ng<gvl<!
6/ G{<cbg<gvl<!
7/ ghizqbg<gvl<!
8/ Gliqbg<gvl<!
9/ dt<ng<gvl<< < << < << < <!
$zqbg<gvg<!GxqG{l<< < << < << < <!
• -f<Ofib<!fiOug<giMme<!$zk<kix<!Gk<KuK!Ohix<!Gk<kjz!
djmbK/!
• $zq!ns<svl<!we<hK!fiuqz<!d{<mieiz<?!fiuieK!ouf<K!
lih<Ohiz<!ouTk<K!njmbigh<!hx<Xkz<!
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• $zq!wEl<!nke<!ohbi<g<G!yh<higs<!$zk<kix<!Gk<Kkz<!Ohiz<!
Gk<kz<!
• nf<fiuqz<!uPuPh<hie!ou{<jlbie!fQI!Svk<kz<?!out<tiuqbqe<!
OhiK!uQSl<!dui<l{<{qe<!fix<xl<!Ohie<x!fix<xl<!fiuqzqVf<K!
outqOb!uQSkz<!
• uif<kqbikz<!
• out<jtg<Ogijp!outquvg<%cb!“out<Otig<gitl<”!
• fQIOum<jg!
• jggt<?!dml<H!-jugtqz<!gVjlfqxL{<mikz<!
• kjzuzqk<kOziM!Ofikz<!
• ogicb!Svr<gib<kz<!
• -Mh<H!gMk<kz<!Ohie<x!G{r<gt<!gi[l</!
fiouf<K! ! ! ! ! .! Glossits 
hjmbig!ouTk<K!lih<Ohiz! ! .! Coated tongue 
$zk<kiz<!fiUx<Gk<kz<! ! ! .! Pain on the tongue 
uPuPk<k!ou{<{QX! ! ! .! Excess salivation 
out<tiuq!dui<!l{<{qe<!fix<xl<!! .! Fetid breath 
out<Otig<gizl<! ! ! ! .! Regurgitition 
k{<{QI!Oum<jg! ! ! ! .! Dipsia 
giz<!jggTme<!gVjl! ! ! .! Lethargic 
kjzuzq! ! ! ! ! .! Headache 
kQb!Svl<! ! ! ! ! .! High Grade Fever 
fQkqbg<gvg<G{l<Q < < <Q < < <Q < < <!
• fQkqbg<gvl<?!fiuqz<!d{<mieiz<!fiuieK!nkqgligilZl<?!
GjxbilZl<!fMk<kvlib<!dm<hg<gl<!Oug<gim<miz<!squf<K!
nke<Olz<!ou{<jlbie!lijuh<Ohiz<!yV!ohiVt<!hmIf<kqVg<Gl</!
• nKUl<!=vh<hjs!-z<zilz<!dzi<f<kqVg<Gl</!
• uib<!uvTl</!
• uib<!jgk<kz<!
• ofR<S!wiqkz<!
• Gtqi<kz<!
• kjzuzqk<kz<!
• nkqgligs<!Svl<!uQsz<!
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we<El<!Gxqgt<!Wx<hm<miz<!fQkqbg<gvl<!weh<hMl</!
dm<squf<K! ! ! . Redness 
outqbqz<!lih<Ohiz<! ! .! Superficiely white coated tongue 
dzi<f<K!uib<! ! .! Dryness of mouth 
ofR<osiqU! ! ! .! Burning Sensation at Retrosternal 
kjzuzq! ! ! .! Headache 
SvlqVf<K!uQsz<! ! .! High grade fever 
Osikqbg<g<<< vg<!GxqG{l<< << << <!
• Osikqbg<gvl<!we<hK!fiuqz<!d{<mieiz<?!nh<OhIg<Ogx<h!fiOukz</!
• nf<k!fijuk<!okimi<f<K!fqxlieK!hz<zg<G!fqxl<!OhizqVk<kz</!
• utqbpz<!ficgt<!dmzqz<!-Vg<Gl<!Ofibqe<!Ke<hk<kiz<!
KcKck<k!ficbig!fmk<kz</!
• kjz!gMjlbig?!-ck<kOziM!kjz!uzqk<kz</!
• gizqe<!gQz<gt<?!giz<?!gj{g<giz<!-jugt<!lqgUl<!
Kjtk<kziZ{<miuK!Ohiz<!Ofikz</!
• Svr<gib<kz<!
• ubqX!gpqkz<!
• uif<kqbikz<?!ubqx<xqz<!dt<tqZl<!outqbqZl<!Yb<uqe<xq!wiqkz<!
we<El<!-g<Gxqgt<!-Vf<kiz<!Osikqbg<gvl<!weh<hMl</!
fi!Oukz<! ! ! ! .! Glossitis 
hz<zPg<GXl<!! ! ! .! Change of Teeth Color!
fic!Oukjebib<!KcKck<kz<! .! Tachycardia 
kjzbqc!Ohiz<!bqck<kz<! ! .! Headache 
g[g<giz<!Ofikz<! ! ! .! Pain 
Svl<!uQSkz<! ! ! ! .! Fever 
gpqkz<!! ! ! ! .! Diarrhoea 
uif<kq!! ! ! ! .! Vomitting 
ubqx<xqEt<Tl<!Olx<HxLl<!wiqkz<!.! Gastritis! !
uQQQQpq!ng<g<<< vg<GxqG{l<< << << <!
• uQpq!ng<gvl<!we<hK!fiuqz<!d{<mieiz<!fi!kck<kz<?!!
• osf<fqxl<!Ohiz<!fi!squk<kz<!
• uib<!Oug<gimikz<!
• dmz<!gVjlfqxljmkz<!
• lqg<g!fQIOum<jg!
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• ofR<sjmh<H!
• =vz<!ouf<K!Ofikz<!
• lqgg<!Gtqi<kz<!
• kjz!lqGkqbig!Ofikz<!
we<El<!-g<Gxqgt<!gi{h<hm<miz<!uQpq!ng<gvl<!weh<hMl</!
fi!kck<kz<! ! ! .! Inflammation of tongue 
fi!squk<kz<! ! ! .! Redness tongue 
uib<!Oug<giM! ! .! Stomatitis 
kjzOfikz<! ! ! .! Headache 
ofR<sjmh<H! ! ! .! Choking of Chest 
=vz<!ouf<K!Ofikz<!! .! Ulcerative pain 
Gtqi<kz<! ! ! .! Chills 
G{<cbg<gvg<!GxqG{l<< < < << < < << < < <!
• G{<c!ns<svl<!fiuqz<!d{<mieiz<!=vz<!ouf<K!fi!lqgg<!
ogikqh<hjmf<K!lqgUl<!squf<kqVg<Gl</!
• uib<!%Sl<!!
• -Vlz<!
• ubqX!gpqkz<!
• dmz<!lqgg<!gMk<kz<!
• ofR<S!giqk<K!Yg<gitqk<kz<!
• uqziuqe<!yVhg<gl<!Ofikz<!
• fQIOum<jg!
!! Ngqb!-g<Gxqgt<!gi{h<hm<miz<!G{<cbg<gvl<!weh<hMl</!
G{<cbg<gvl<!)OuX!ogit<jg*< < < << < < << < < < !
• Gpf<jkgtqe<!-Mh<Hg<G!Olz<!Svlcg<Gl<!
• dml<H!lQe<!dml<jhh<!Ohie<X!out<jt!fqxliGl</!
• sqXfQI!lR<st<!fqxlibqxr<Gl<!
• ws<suib<!kqCove<X!SVg<ogeg<Gk<Kl<!
• dml<H!-jtg<Gl</!
• dml<H!gMg<Gl</!
• lpjzs<!osiz<zieK!OhsLcbikhc!Gvz<!gMg<Gl</!
!! Ngqb!-g<Gxq!G{r<gt<!g{<miz<!G{<cbg<gvl<!weh<hMl</!
! !
 10
=vz<!ouf<K! ! ! .! Pain abdomen 
fig<ogikqk<okPf<K! ! .! Soreness of Tongue 
-Vlz<! ! ! .! Cough 
ubqX!gpqkz<!! ! .! Diarrhoea 
uqziOfikz<! ! ! .! Pain in Loin 
fQIOum<jg! ! ! .! Polydipsia 
dmz<!-jtg<Gl<! ! .! Emaciation 
ghizqbg<gvg<!GxqG{l<< < << < << < <!
• ghizq!ns<svl<!fiuqz<!d{<mieiz<!GmZl<!=vZl<!ouf<K!OfiGl<?!
• oki{<jmbqz<!gics<OsiX!ohir<GuKOhiz<!ohir<Gl<!
• nhibgvlig!fi!OuGl</!
• Jf<kil<!fitqz<!nu<!Oug<gim<cz<!ouck<K!GVkq!ucBl</!
• kjzOfiGl<!
• dmz<!uzqg<Gl<!
• dmz<!hTuib<k<!Okie<Xl<!
• uqmis<!Svlcg<Gl</!
• ofR<Suzq!d{<miGl<!
• ubqX!ofif<K!-jvf<K!gpqBl<!
!! -g<Gxqgt<!gi{h<hm<miz<!ghizqbg<gvl<!weh<hMl</!
Gmz<!=vz<Ofib<! ! ! ! .! Intestinal diseases 
ofR<S!gics<!OsiX!Ohiz<!ohir<gz<! .! Regurgitation!
fi!ouf<K! ! ! ! ! .! Glossitis 
fiouck<K!GVkq!uckz<! ! ! .! Bleeding from tongue 
dmz<!uzq! ! ! ! ! .! Body pain 
Svl<! ! ! ! ! ! .! Fever 
ofR<S!Ofikz<! ! ! ! .! Retrosternal pain 
ofif<kqjvf<K!Ohkq! ! ! ! .! Dysentery 
!
Gliqbg<gvg<!GxqG{l<< < << < << < <!
• Gliq!ns<svl<!fiuqz<!d{<mieiz<!wf<kh<!ohiVjtBl<!d{<{!
LcbilZl<?!Gcg<g!LcbilZl<!fi!%Sl</!
• fi!Kcg<Gl<!
• dml<hqz<!sjk!OfiGl</!!nkeiz<!Ke<hl<!lqGl</!
• -v{<M!g{<gTl<!OfiGl</!
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• Svlcg<Gl<!
• uib<!jgg<Gl<!
• Ouglib<!ncg<gc!uif<kqobMg<Gl</!
• d{<{ig<G!utVl</!
• hz<!lR<st<!fqxligUl<?!kjzbqzqVf<K!&g<gqe<!upqbig!&e<X!
fit<ujvg<Gl<!osf<fQI!ucBl</!
!! Ngqb!-g<Gxqgt<!gi{h<hm<miz<!Gliqbg<gvl<!weh<hMl</!
!
sjkOfib<! ! ! .! Growth in the mouth propably growth of  
uvulla 
g{<O{ikz<! ! ! .! Conjuctivitis 
Svl<! ! ! ! .  Fever 
uib<jgk<kz<!! ! .! Better taste 
uif<kq!lqgz<! ! ! .! Vomiting 
hz<!lR<stikz<!  - Change of colour (Yellow) 
&g<gqz<!vk<kl<!uckz<! .! Epistaxis 
d{<{ig<G!lqg!uti<kz<! .! Uvulitis 
!
!!!! -kqz<!Nb<Ug<gm<Mjv!kjzh<hqz<!dt<t!dt<!ng<gvk<kqe< < << < << < < <!GxqG{r<gt<!
gQp<uVliX!
! &g<G!fQIh<!hib<s<s!ziGl<!
! ! Lglqg!outqiqh<!OhiGl<!
! fig<GOl!ouTk<Kh<!H,g<Gl<!
! ! fihqzi!biuq!Okie<Xl<!
K~g<gLR<!SvL!olk<kk<!
! ! K[g<!ogek<!k{<{QIuir<Gl<!
! kQIg<guqg<!G{r<gt<!g{<miz<!
! ! kqgLt<ts<!svL!liOl!
• df<kqbqz<!dm<hg<gl<!ouf<K!H{<{igq!nkeqeqe<X!Nuq!Okie<xq!
OlZg<Gg<!gqtl<hq!kjzbqz<!Lm<c!fQvib<?!nf<fQI!&g<gqe<!upqbib<!
yPGl</!
• nf<fQI!Lgl<!Lkzqb!Olz<!Ofig<GXh<Hgtqz<!Ogik<Kg<!
ogit<ukeiz<!GVkq!ogm<M!nl<Lgl<!Lkzqbux<xqz<!osf<fqxl<!
fQr<gq!ouTg<Gl</!
• fig<Gl<!ouTk<K!nkqz<!ou{<!fQX!H,k<kqVg<Gl</!
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• K~g<gl<!d{<miGl</!
• Svlcg<Gl<!
• kqCove<X!k{<{QI!Oum<jgB{<miGl</!
&g<G!fQI!hib<s<sz<! ! .! Running nose 
lqglqg!ouTk<kz<! ! .! Pallor face 
fi!ouTk<kz<! ! .! Coated tongue 
Svl<! ! ! ! .! Fever 
fQI!Oum<jg! ! ! .! Polydipsia 
3/!hqt<jth<!hq{q!lVk<Kul<!)higl<!2*< < < < << < < < << < < < < !
!! ng<gvk<kqe<!ujggt<!gQp<g{<muiX!%xh<hm<Mt<tK!
2/ -vk<k!ns<svl<!
3/ -jth<hg<gvl<!
4/ dkm<mg<gvl<!
5/ dt<ns<svl<< < << < << < <!
6/ gmuibg<gvl<!
7/ ghizqbs<svl<!
8/ G{<cns<svl<!
9/ Gliqbs<svl<!
:/ sqr<rU!ng<gvl<!
21/ $zqbs<svl<!
22/ Osikqbg<gvl<!
23/ okif<k!ng<gvl<!
24/ fQkqbg<gvl<!
25/ hqz<zq!ng<gvl<!
26/ uQpq!ng<gvl<!
4/!hvvisOsgvk<kqz<!7!ujg!ng<gvLl<!sqz!ng<gvOhkr<gTl<!%xh<hm<Mt<te/!!< < < < < < < < < << < < < < < < < < << < < < < < < < < <
nju!
2/ gXk<k!ng<gvl<!
3/ squf<k!ng<gvl<!
4/ out<jt!ng<gvl<!
5/ dt<!ng<gvl<< < << < << < <!
6/ =vzg<gvl<!
7/ uibg<gvl<!
8/ ng<gvSvl<!
9/ ng<gv!Svsf<fq!
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:/ ng<gvg<gqvf<kqouh<H!
21/ out<jtbg<gvouh<H!
22/ gXk<kg<gvouh<H!
23/ squk<kg<gvouh<H!
24/ ng<gvh<hMue<!
-kqz<!dt<ng<gvk<kqe<!GxqG{r<gt<< < < < < < << < < < < < << < < < < < <!
! “kjzbqje!uzqg<Gr<!giBf<!kgLm!zuqf<K!H{<{ib<s<!
! ! sqjzobeubqX!&kqs<!osVlqBt<!tEr<gq!Lm<mib<!
fqjzobeg<!giz<gi!biK!ofb<h<hx<xib<s<!sqbzib<s<!S{<mib<!
! ! djzUxg<!gpqk<K!fiX!Lt<tqzg<!gvf<kie<!xQOk!
2/ kjzuzq!
3/ gib<s<sz<!
4/ dmz<!ouf<K!H{<{iGl<!
5/ ubqX!gz<Ohiz<!DKl<!
6/ osVLl<!
7/ dt<tEr<Gl<!
8/ Lm<M!giz<gibiK!
9/ ofb<!OhiZl<!sQp<!OhiZl<!lzl<!gpqf<K!fiXl<!
5/!Nk<lvm<silqi<ki<kl<!F~zqz<!ng<gvl<!9!ujgh<hMl<!we!%xh<hm<Mt<te!nju/< < < < < < < < < < < < << < < < < < < < < < < < << < < < < < < < < < < < < !
2/ $zq!ng<gvl<!
3/ fQzq!ng<gvl<!
4/ Osikq!ng<gvl<!
5/ uQpq!ng<gvl<!
6/ G{<c!ng<gvl<!
7/ ghizq!ng<gvl<!
8/ Gliq!ng<gvl<!
9/ dt<!ng<gvl<< < << < << < <!
-kqz<!dt<!ng<gvk<kqe<!GxqG{r<gt<< < < < < < << < < < < < << < < < < < <!
• &g<gqz<!fQI!ucBl<!
• LgLl<!fig<Gl<!ouTg<Gl<!
• fig<gqz<!Nuq!Okie<Xl<!
• K~g<gl<!
• Svl<!
• k{<{QI!kigl<!lqGf<K!gi[l</!
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6/!Gl<hLeq!hizuigml<!F~zqz<!ng<gvl<!8!ujgh<hMl<!we!%xh<hm<Mt<tK/!!< < < < < < < < < << < < < < < < < < << < < < < < < < < <
nju!
2/ $zq!ng<gvl<!
3/ fQzq!ng<gvl<!
4/ ghizq!ng<gvl<!
5/ Gliq!ng<gvl<!
6/ G{<c!ng<gvl<!
7/ Osikq!ng<gvl<!
8/ uQpq!ng<gvl<!
!! -u<uiX!yu<ouiV!F~z<gtqZl<!ng<gvk<kqe<!ujggt<!uqtg<gh<hm<Mt<te/!
!
! !
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Lg<Gx<x!OuXhiMgt<< < << < << < <!)Pathogenesis) 
 
sqk<k!lVk<Kuk<kqz<!Lg<Gx<xr<gtqe<!nch<hjmbqz<!Ofib<gt<!
ujgh<hMk<kh<hm<Mt<te/!nju!!
!
ujgh<hiMgt<!)< << << < Classification) 
 uikl<!.!21!
! hqk<kl<!.!6!
! ghl<!.!6!
!
I. uikl<!)<<< Vatham) 
1. ucuk<ke<jl< << << < !
• F{<jl!)n[k<Kul<*!
• ofib<jl!)gcelqe<jl*!
• k{<jl!)Gtqi<s<sq*!
• oul<jl!)dm<c{l<*!
!! k{<jl?! oul<jl! -u<uqv{<miz<! uVl<! yh<Hvuqe<jl! )sVs<sjv*!
we<heuil</!
!
3/!uiPlqml<<<<!
! nhiee<?! lzl<?! -mgjz?! df<kqbqe<! gQp<&zl<?! gilg<ogic?! -Mh<H!
wZl<H?!Okiz<?!fvl<Hg<%m<ml<?!gQz<gt<?!lbqi<g<giz<gt<?!De<?!
!
4/!-bx<jgh<h{<H< < << < << < < !
• Dg<gL{<mig<gz<!
• &s<S!uqmz<?!&s<S!uir<gz<!
• leolipq!olb<gTg<Gs<!osbjzk<kvz<!
• lzl<!Lkzqb!hkqeie<G!Ougr<gjt!outqh<hMk<kz<!
• sivl<!Lkzqb!WP!dmx<kiKg<gTg<Gl<!yk<k!fqgp<s<sqjbk<!kvz<!
• Jl<ohixqgm<G!ue<jljbg<!ogiMk<kz<!
! !
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5/!hqiqUgt<<<<!
! -0K! ye<xibqVh<hqEl<! ke<! -ml<?! okipqz<! Lkzqbux<xiz<! hk<K!
ujgh<hMl<!nju/!
! uikl<<<<! osbz<<<<!
dt<ng<gvk<kqz<!< < < << < < << < < <
uikk<kqe<!fqjz< << << < !
2/! hqvi{e<! • &s<Suir<gz<?!&s<SuqMkz<?!!
• d{ju!osiqg<gs<!osb<kz<!
-bz<H!
3/! nhiee<! • lzszk<jkk<!kt<Tl</!!!
• Nseuijbs<!SVg<Gl</!!
• ne<esivk<jk!OsvOu{<cb!
-mr<gtqz<!Osi<h<hqg<Gl<!
-bz<H!
4/! uqbiee<! • dXh<Hg<gjt!fQm<mUl<!lmg<gUl<!
osb<Bl<?!!
• hiqsr<gjtbxqBl<?!!
• d{<[l<!d{uqe<!sivk<jk!
nu<uqmr<gtqz<!fqvh<hqk<K!
dmjzg<gig<Gl</!
-bz<H!
5/! dkiee<! • dkvig<gqeqbqz<!-Vf<K!Okie<xq!
d{uqe<!sivk<OkiM!!
%cbqVf<K!njk!nr<OgOb!
fqXk<Kl<?!njk!outqh<hMk<kqBl<!
gzg<gqBl<!uVkz<!osb<Bl<!
hikqh<H!)ubqX!
ouf<K!nK!
uib<upq!
outqh<hm<M!
H{<j{!
Wx<hMk<Kl<*/!
6/!! sliee<! • fihqbqzqVf<K!giz<ujvg<Gl<!
sleib<h<!hvuqh<hib<f<K?!lx<x!
uiBg<gjt!lqR<s!ouim<milz<!
lmg<gqs<!siqh<hMk<kqs<!Osvh<h{<[l</!
• nXSjugjtBl<?!ne<el<?!
k{<{QI!Ngqbux<jxBl<!
slh<hMk<kq!dml<hqz<!OsVl<hc!
osb<Bl</!
hikqh<H!
)k{<{QI!Oum<jg!
d{<miGl<*!
7/! fige<! • nxqju!wPh<Hl<!
• fz<z!h{<Hgjth<!hiMuqg<Gl<!
• g{<gjt!kqxg<Gl<hc!osb<Bl<!
• g{<gjt!-jlg<Gl<!
• lbqi<gjt!sqzqIg<gh<h{<[l<!
-bz<H!
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8/! %Ile<! • lekqzqVf<K!gqtl<hqg<!
g{<{qzqVf<K!-jljbg<!
ogim<Muqg<Gl</!
• ogim<miuq!uqmh<h{<[l<!
• hzl<!d{<Mh{<[l<!
• g{<gjtk<kqxg<gUl<!&mUl<!
h{<[l<!
• g{<gtqeqe<X!fQjv!uqps<osb<Bl<!
-bz<H!
9/! gqVgve<! • fiuqx<gsqU!
• fisqbqz<!gsqU!
• hsq!d{<mig<Gl<!
• ye<jx!fqjek<kqVg<gs<!osb<Bl<!
• Kl<lz<!
• -Vlz<!
hikqh<H!)fig<gqz<!
H{<?!fi!
lih<hcf<K!gi{z<*!
:/!! Okukk<ke<! • Osil<hjzBl<!
• dmz<!Liqk<kjzBl<!d{<mig<Gl<!
• s{<jm!ogit<tz<!
• lqg<gOgihl<!d{<mig<Gl<!
hikqh<H!!
)K~g<glqe<jl!
d{<miGl<*!
21/! keR<osbe<! • &g<gqzqVf<K!kck<K!dml<H!
LPjlBl<!uQr<gh<h{<[l<!
• gikqz<!gmz<!Ohiz<!-jvBl<!
• -xf<Kuqce<!gix<oxz<zil<!
outqh<hm<m!hqe<ei<!&e<xiuK!
fitqz<!kjz!ouck<khqe<!kie<!
OhiGl</!
!
!
 dt<!ng<gvl<!Ofibitqgtqz<!dkiee<?!gqVgve<!hikqg<gh<hm<M!
-Vf<kK/!sqziqz<!sliee<?!Okukk<ke<!hikqg<gh<hm<cVf<kK/!
! !
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hqk<kl<< << << <!
2/ucuk<ke<jl< << << < !
 ouh<hl<!
 %Ijl!
 ofb<h<H!
 ofgqp<s<sq!
 -bg<gl<!
3/!uiPlqml<<<<!
! hqr<gjz?!hqvi{uiB?!fQIh<jh?!&zig<gqeq?!-Vkbl<?!kjz?!ogih<H,p<?!
df<kq!-jvh<jh?!uqbi<ju?!fiuqZ~Xgqe<x!fQI?!osf<fQI?!sivl<?!g{<?!Okiz</!
4/!-bx<jgh<h{<H< < << < << < < !
 osiqh<hqk<kz<!
 oul<jl!
 hiIju!
 hsq!!
 fQIOum<jg!
 Sju?!ytq!
 fqjeh<H!
 nxqU!
 ue<jl?!ole<jl!d{<mig<Gl</!
5/!hqiqUgt<<<<!
! hqk<kl<< << << <! osbz<<<<! dt<ng<gvk<kqz<!< < < << < < << < < <
hqk<kk<kqe<!fqjz< < << < << < < !
2/! nex<hqk<kl<! • kQbqe<!h{<HjmbK!
• uqjvh<jhg<Gl<!
hg<Guisbk<kqx<Gl<!
-jmbqzqVf<K!kQbqe<!
G{k<jk!lqGkqbigh<!ohx<X?!
fQI!ucuLt<t!ohiVt<gjt!
uxts<!osb<Bl</!
• d{<m!d{ju!osiqg<Gl<!
hcosb<Bl</!
hikqh<H!)ubqX!
ouf<K!nK!
uib<upq!
outqh<hm<M!
H{<j{!
Wx<hMk<Kl<*!
3/! -vR<sghqk<kl<! • osf<fQjv!lqGkqh<hMk<Kl<!
• -jvg<!GmzqzqVf<K!ogi{<M!
hikqh<H!)GVkq!
ogm<M!Lgl<!
osf<fqxl<!fQr<gq!
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d{uqzqVf<K!hqiqf<K{<mie!
siXg<Gs<!osf<fqxk<jk!kVl</!
ouTg<Gl<*!
4/! sikgh<hqk<kl<! • klvgk<kqeqe<X!lel<?!Hk<kq!
hx<X!-ux<jxg<!ogi{<M!
uqVh<hlie!okipqjzs<!osb<K!
Lcg<Gl<!
hikqh<H!
)upg<glie!
h{qgjt!osb<b!
sqvll<*!
5/! NOzisghqk<kl<! • g{<gTg<G!ohiVm<gjt!
okiquqg<Gl<!
• ohiVt<gtqe<!ucuk<jk!
nxqkz<!
-bz<H!
6/! hqvisg!hqk<kl<! • OkiZg<G!ytqjbogiMk<K!
ytqvs<!osb<Bl</!
hikqh<H!)Lgl<!
ouTk<K!gi{z<*!
!
 dt<!ng<gvl<!Ofibitqgtqz<!nex<hqk<kl<?!-vR<sg!hqk<kl<?!
sikgh<hqk<kl<?!hqvisg!hqk<kl<!!hikqg<gh<hm<M!-Vf<kK/ 
III. ghl<<<<!
2/!ucuk<ke<jl< << << < !
 k{<jl!
 ofb<h<H!
 lf<kl<!
 uPuPh<H!
 ole<jl!
 kq{<jl!
3/uiPlqml<<<<!
! slieuiB!–!SpqLje!–ouf<fQI.!Ng<gqje!–!fig<G!–!d{<{ig<G!–!
ogiPh<H!–!ls<js!–!GVkq!.!&g<G!.!liIH!–!fvl<H!–!wZl<H!.!&jt!–!
ohVr<Gmz<!.!g{<!.!gQz<gt</!
!
4/!-bx<jgh<h{<H< < << < << < < !
• Jbl<!ke<!-bx<jg!fqjzbqz<!fqjzk<kz<!.!ofb<h<H?!!
• gQz<gtqe<!njlh<hqe<!gm<Mgt<?!!
• ohijxBjmjl?! nkiuK! hsq?! fQIOum<jg?! Kbvl<?! gzg<gl<?! ouh<hl<!
-jugjth<!ohiXk<Kg<!ogit<Tkz</!
! !
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5/hqiqUgt<<<<!
! Jbl<<<<! osbz<<<<! dt<ng<gvk<kqz<!< < < << < < << < < <
Jbk<kqe<!fqjz< << << < !
2/! nuzl<hgl<! • -K!FjvbQvzqzqVf<K!ogi{<M!
kqiqg^<kiek<kqx<Gl<!d{uqe<!
sk<kiz<!klvgk<kqx<Gl<!
nch<hjmbibqVf<K!ke<!
-bx<jg!ofgqp<s<sqk<!
ke<jljbg<!ogi{<M!lx<x!
fie<G!Jbr<gm<M!hx<Xg<Ogimig!
dt<tK!
-bz<H!
3/! gqOzkgl<! • -jvh<jhbqzqVf<K!ogi{<M!
d{<{h<hm<m!d{Uh<!ohiVjt!
fQI!Lkzqbux<jx!=vh<hMk<kq!
olk<okes<!osb<Bl<!
hikqh<H!)ubqX!
ouf<K!uib<upq!
outqh<hm<M!
H{<j{!
Wx<hMk<Kl<*!
!
4/! Ohikgl<! • -K!Sjuohixqbigqb!fiuqeqz<!
fqe<X!d{<[gqe<x!Sjugjt!
nxquqg<Gl<!okipqjzHiqBl</!
hikqh<H!)fiuqz<!
H{<?!fi!ouTk<K!
lih<!hcf<kK!Ohiz<!
gi[l<*!
5/! kx<hgl<! • -K!kjzbqeqe<X!g{<gTg<G!
Gtqi<s<sqjbk<!kVl<!
-bz<H!
6/! sf<kqgl<! • H,m<Mg<gtqz<!fqe<X!-bx<jgbib<!
wz<zi!gQz<gjtBl<!
ye<Oxiomie<X!ohiVk<kqk<!ktvs<!
osb<Bl<!
-bz<H!
!
 dt<!ng<gvl<!Ofibitqgtqz<!gqOzkgl<?!Ohikgl<!hikqg<gh<hm<mK/!
!
WP!dmx<kiKg<gt<< < << < << < <!
• WP!dmx<kiKg<gTl<!kk<kl<!-bx<jgh<h{<OhiM!-Vf<kize<xq!njugt<!
osb<Bl<!okipqz<!fe<G!fjmohxiK/!
• WP!dx<kiKg<gTl<!kk<kl<!ntuqeqe<Xl<!lqGf<kiZl<?!Gjxf<kiZl<!
nke<ke<!-bx<jgk<!okipqz<!OuXhMl</!
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!
!
dmx<kiKg<gt<< < << < << < <! h{<H<<< !
dt<ng<gvk<kqz<!< < < << < < << < < <
dmx<!kiKg<gtqe<!< < << < << < <
fqjz!
2/! sivl<! • dmjzBl<?!lek<jkBl<!Dg<gLxs<!
osb<uK!
hikqh<H!
)K~g<glqe<jl!
Wx<hMl<*!
3/! osf<fQI! • nxqU?!ue<jl?!ytq?!osVg<G?!yzq!
-jugjt!fqjzg<gs<!osb<Bl<!
hikqh<H!)Lgl<?!
fig<gqz<!osf<fqxl<!
fQr<gq!ouTg<Gl<*!
!
4/! D{<! • dmzqe<!dVuk<jk!nke<!
okipqx<gq{r<g!njlk<kz<!
• we<jh!uti<k<kz<!
hikqh<H!
)uib<hGkqbqz<!
D{<!Ogmjmf<K!
H{<!d{<mikz<*/!
5/!! ogiPh<H! • dXh<HgTg<G!ofb<h<Hh<!hjs!Dm<c!
gcelqe<xq!-bg<Gl<!
-bz<H!
6/!! wZl<H! • dmjz!yPr<G!hm!fqXk<kq!juk<kz<!
• ole<jlbie!dXh<Hgjth<!
hiKgik<kz<!
• dmz<!njsuqx<G!
nch<hjmbibqVk<kz<!
-bz<H!
7/! &jt! • we<Hg<Gt<!fqjxf<K!njugTg<G!
ue<jlBl<!ole<jlBl<!kVl<!
-bz<H!
8/! ou{<{QI! • gVk<Okix<xk<kqx<G!Lkzib<!fqx<hK! . !
!!
 dt<ng<gvl<!Ofibitqgtqz<!sivl<?!osf<fQI?!D{<!hikqg<gh<hm<M!
-Vf<kK/!
w{<ujgk<!Oki<U< < << < << < < !
! w{<ujgk<!Oki<Ugt<!we<hK!sqk<k!lVk<Ku!Ljxbqz<!Ofijb!
g{q<h<hkx<G!dkUl<!NBkr<gtiGl</!
! “fic!^<hiqsl<!fifqxl<!olipq!uqpq< < << < << < < !
! lzl<!&k<kqvl<!-ju!lVk<KuviBkl<< < < < << < < < << < < < <”!
.!Ofib<!fimz<!Ofib<!Lkz<!fimz<!Lkz<!higl<!!!!!!!
!!h/w{</381!
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2/ fic!)Pulse) 
3/ ^<hiqsl<!(Touch) 
4/ fi!)Tongue) 
5/ fqxl<!)Colour of the skin) 
6/ olipq!)Speech) 
7/ uqpq!)Eye) 
8/ lzl<!)Faeces) 
9/ &k<kqvl<!)(Urine) 
2/fic!
! w{<ujgk<!Oki<Ugtqz<!sqxf<kK!fic/!!
 dt<ng<gvk<kqz<! keqk<k! nz<zK! okif<k! fic! gi{h<hm<mK/!!
ohVl<hiZl<!hqk<k!ghfic!gi{h<hm<mK/!
3/! <^hiqsl<< << << <!
! Ofibitqbqje! okim<M! hiIk<kzqeiz<! dmzqe<! gir<jg?! Gtqi<s<sq?!
uqbi<ju?! lklkh<H! ke<jl?! uxm<sq?! H{<?! uQg<gl<?! dmz<olzqU?! gz<zQvz<?!
l{<{Qvz<!Ngqb!-jugjt! <^hiqsqk<K!d{vzil</!
 dt<ng<gvk<kqz<!sqziqz<!Svl<!gi{h<hm<mK/!
!
4/!fi!
! fi?! hx<gt<?! =X?! dkM! -jugtqe<! fqxl<?! H{<?! uti<s<sq?! hcU!
Ngqbjugjt!nxqbOu{<Ml</!
 dt<!ng<gvk<kqz<!fiuqz<!H{<?!dkm<cz<!H{<?!ouch<H?!fi!ouTk<K!
li!hcf<kK!Ohiz<!gi{z<!Ohie<xju!gi{h<hm<mK/!
5/!fqxl<<<<!
! dmzqe<! fqxl<! nkiuK! outqxqb! fqxl<?! fQzl<! hiiqk<kz<?! lR<stqk<kz<?!
gVfqxl<! njmkz<! -jugjt! uik?! hqk<k?! gh?! okif<k! Lg<Gx<x! GxqgTme<!
nxqbzil</!
 dt<!ng<gvk<kqz<!sqziqz<!Lgl<!Lkzqbux<xqz<!osf<fqxl<!fQr<gq!
ouTk<K!gi{h<hm<mK/!
6/!olipq!
 dt<!ng<gvk<kqz<!sqziqz<!uibqz<!H{<!-Vh<hkiz<!OhSukqz<!sqvll<!
gi{h<hm<mK/!
! !
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7/uqpq!
! uqpqjb!hiqOsikje!osb<K!g{<{qe<!fqxl<?!fQIuckz<?!Hjmk<Kg<!gi{z<!
-jugjt!nxqbzil</!
 dt<!ng<gvk<kqz<!sqziqz<!g{<ouTk<K!gi{h<hm<mK/!
8/!lzl<<<<!
! uik! Ofibitqgtqz<! lzl<! gVk<K! ux{<Ml<?! hqk<k! Ofibitqgtqz<!
fMk<kvligUl<?! lR<st<! gzf<k! squh<H! fqxligUl<?! gh! Ofibitqgtqz<!
ou{<jlbigUl<!Fjv!gzf<K!nkqg!ntuigUl<!gi{h<hMl</!
!
9/&k<kqvl<!< << << < !
fQIfqxg<Gxq!ofb<GxqQ < <Q < <Q < < !
! “nVf<Kli!xqvkLl<!nuqOvi!klkib<< < << < << < <!
! n0gz<!nzi<kz<!ngi< < << < << < < zU,{<!kuqi<f<< < << < << < <kpx<<<<!
! Gx<xt!uVf<kq!dxr<gq!jujx< < << < << < < !
! Ncg<!gzsk<!kiuqOb!giKohb<< < << < << < <!
! okiV!L%If<!kg<gezg<!Gm<hM!fQiqe<< < < < Q << < < < Q << < < < Q <!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe< < < < << < < < << < < < < ”!
.!Ofib<fimz<!Ofib<!Lkz<!fimz<!higl<< < < < < << < < < < << < < < < <.2!h/w{</393<<< !
!
!! d{<[gqe<x! nXSjuh<! ohiVt<gTl<! Oux<Xjl! njmbilZl<!
hsqg<Gk<kg<ghc! Gjxk<kz<?! nkqgiqk<kz<?! gizl<! kh<Hkz<! Lkzqb! Gx<xr<gt<!
-z<zilz<! dxr<gq! uqcbx<! gizk<kqz<! hcg! hik<kqvk<kqz<! fQjv! NuqOhigikhc!
ohb<k! 4¾! fipqjgg<Gt<! nke<! fqxg<GxqjbBl<?! nkqz<! w{<o{b<! uqm<M!
ofb<GxqBl<!hiIg<g!Ou{<Ml</!
!
fQIg<GxqQ <Q <Q < !
! lVk<Ku!gjz!uz<zui<g<G!Ofijb!g{qh<hkx<G!fQIg<Gxqjbg<!gim<cZl<!
sqxf<kK!Ouxqz<jz/!
! “ki<g<g!sik<kqiqgOtiI< < << < << < < !
! fic!uIg<glil<!fic!ke<eqz<< < < << < < << < < <!
! uVuK!lbg<g!<<< ole<Ox<<< !
! dx<x!fQI!hiQm<js!bxqf<Ok< Q Q < << Q Q < << Q Q < < !
! Bjvk<keiqkx<G!Ofvib<< < << < << < <!
! lx<oxiV!uqkq!F~zqz<jz< << << < !
! lVk<Kug<gjz!uz<OziIg<Og< < < << < < << < < < ”!
! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!
! !
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fqxl<! .! Colour of urine 
l{l<!!.! Smell 
wjm! .! Specific gravity 
Fjv! .! Frothy in nature of urine 
wR<sz<!.! Amount of urine per day 
 dt<ng<gvk<kqz<!fQIg<Gxq!siqbie!fqjzbqz<!gi{h<hm<mK/!
!
ofb<Gxq<<< !
uikfQiqe<!ke<jlgt<Q < < <Q < < <Q < < <!
! “nxoue!fQ{<ce0Og!uikl<Q < <Q < <Q < <” 
!
!! w{<o{b<!Ktq!hil<jhh<!Ohiz<!fQ{<miz<!nK!utqOfijbg<!gim<Ml</!
!
hqk<kfQiqe<!ke<jlgt<< Q < < << Q < < << Q < < <!
! “NpqOhiz<!hvuqe<!n0Ok!hqk<kl<< < < << < < << < < <”!
!! w{<o{b<!Ktq!Olikqvl<!Ohiz<!-jmuqm<Mh<!hvuqeiz<!nf<fQI!hqk<k!
Ofijbg<!gim<Ml</!
!
ghfQiqe<!ke<jlgt<Q < < <Q < < <Q < < <!
! “Lk<okik<K!fqx<gqe<!olipquoke<!ghOl< < < < << < < < << < < < < ”!
!! w{<o{b<Ktq!uqm<mK!uqm<muiOx!sqxqKl<!hvuilz<!Lk<Kh<Ohiz<!
fqx<Glieiz<!nf<fQI!Jb!Ofijbg<!gim<Ml</!
!
okif<kfQI< Q< Q< Q !
! “nvuqzipqBl<!Npqbqz<!nvUl<< < << < << < <!
! nvuqe<<<<Lk<Kl<!Npqbqz<!Lk<Kl<< < < < << < < < << < < < <!
! Okix<xqz<!okif<k!Okimr<gtiOl< < < << < < << < < < ”!
 dt<ng<gvk<kqz<!hqk<kl<!hikqg<gh<hm<M!nkje!okimi<f<K!ghLl<!
hikqh<hjmf<K!ohVl<hiziqz<!hqk<kghfQI!gi{h<hm<mK/!
!
Jl<H,kr<gTg<Gl<?!nXSjugTg<GLt<t!yx<Xjl< < < < < < << < < < < < << < < < < < < !
2/ -eqh<H!!.! hqVkquq!+ nh<H!
3/ Htqh<H!!.! hqVkquq!+ OkB!
4/ duIh<H!.!!! nh<H! !+ OkB!
5/ jgh<H!!.! uiB!!+  Ngibl<!
6/ giIh<H!.! OkB!!+ uiB!
7/ Kui<h<H!.!! hqVkquq!+ uiB!
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• Jl<H,kh<! ohiVm<gt<! biUl<! Gtqi<s<sq! nz<zK! ouh<hk<jkh<!
ohx<xqVg<Gl</!
• OkB!H,kl<!nkqgLt<t!ohiVt<gt<!d]<{uQiqbl<!djmbju/!
• npz<Gx<xl<!nkqgiqk<K!dt<ng<gvl<!Ofijb!Wx<hMk<Kl</!!Njgbiz<!
npz<! Gx<xk<jk! lqGkqhMk<Kl<! d]<{uQiqbl<! dt<t! OkB! H,kl<!
nkqgLt<t! Htqh<H?! dui<h<H?! giIh<H! SjuBt<t! ohiVm<gjt! fQg<g!
Ou{<Ml</!
• -kqz<! Htqh<H! liKjt?! ofz<zqg<gib<?! wZlqs<js! hpl<! Ngqbju!
Htqh<hib<! -Vf<k! OhikqZl<! dm<ogit<tqe<! hqk<kl<! sleh<hMl</!!
sQv{gizk<kqz<!-eqh<hig!liXl<!G{l<!-Vh<hkiz<!-jk!d{<{zil</!
hq{qbxqLjxjl!
! hq{qbxqLjxjl!we<hK!dmjzh<!h{qk<kzib!Ofijbk<!okiqf<K!
ogit<Tgqx!yPg<gl<!weh<hMl</!
nju!
2/ ohixqbiz<!nxqkz<!
3/ Hzeiz<!nxqkz<!
4/ uqeikz<!
2/!ohixqbiz<!nxqkz<< << << <!
2/ Okiz<!)olb<*!
3/ fi)uib<*!
4/ g{<!
5/ &g<G!
6/ osuq!we!Jujgh<hMl<!
 dt<ng<gvl<!Ofibitqgtqz<!fig<gqz<!H{<?!uibqz<H{<?!fi!lihcf<K!
ouTk<K!gi{h<hm<me/!!sqziqz<!&g<gqzqVf<K!fQI!gsqkz<!gi{h<hm<me/!
3/!Hzeiz<!nxqkz<< << << <!
2/ Sju!
3/ ytq!
4/ DX!
5/ Yjs!!
6/ fix<xl<!)l{l<*!!we!Jujgh<hMl</!
 dt<!ng<gvl<!Ofibitqgtqz<!sqziqz<!uib<fix<xl<?!Sju!liXhiM?!DX!
Ogmjmkz<!gi{h<hm<me/!
! !
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4/!uqeikz<<<<!
! uqeikzqz<! Ofibitqbqe<! ohbi<?! ubK?! Ke<hr<gtqe<! gizntU?!
kx<Ohijkb! Ofibqe<! uvziX?! Lf<jkb! Ofibqe<! uvziX?! GMl<h! uvziX?!
d{U! hpg<gupg<gr<gt<?! kMh<H,sq! Ohim<m! uvziX! Ofibitqbqe<! s&g!
ohiVtikiv!Oll<him<ce<!fqjz!Ngqb!-jugt<!Ofibitqbqe<!ubjkh<ohiVk<K!
dxuqeiqml<!Ogm<M!nxqbh<hMl</!
!
lVk<Ku!upqLjx!hqe<uVliX< << << < !
2/ gih<H!)Prevention)!
3/ fQg<gl<!)Treatment)!
4/ fqjxU!)Restoration)!
!
2/gih<H!)<<< Prevention) 
 Ofib<!uVukx<G!Le<El<!hqe<El<!Ofibqe<!ke<jl!nkqgiqg<gilz<!-Vg<g!
osb<bh<hMue!NGl</!
!
3/fQg<gl<Q < <Q < <Q < <!
2/!ke<eqjzbqz<!kqiqf<k!Gx<xr<gjt!ke<eqjzh<hMk<k!Ou{<Ml</!
3/!Ofibqe<!GxqG{r<gTg<G!Wx<h!lVf<Kgjt!kvOu{<Ml</!
 dt<ng<gvk<kqz<! hqk<kl<! nkqgligq?! &zikivk<kqz<! -Vf<K!Nuq! gqtl<hq!
-f<Ofijb!d{<mig<Gl</! ! nkeiz<! hqk<kk<jk! slh<hMk<kg<%cb! H,uvS!
w{<o{b<!upr<gh<hm<mK/!
 Ofibitqbqe<! ubK?! wjm?! Ngqbux<jxh<! ohiVk<K! lVf<kqe<! ntU!
upr<gh<hm<mK/!
4/fqjxU!
! Ofib<! Lx<xqZl<! G{lig! lVf<Kgt<! lm<Mlqe<xq! d{U! Ljxgtqz<!
%xqBt<t! hk<kqbr<gjtBl<?! Ofib<! nkqgiqg<gilzqVg<g! nEsiqg<g! Ou{<cb!
osbz<gjtBl<!hqe<hx<x!Ou{<Ml</!
d{ULjx!
2/ wtqjlbie!osiqg<gg<%cb!d{U!
3/ givlqz<zik!d{U!
4/ Htqh<Hl<?!givLl<!H{<j{!nkqgh<hMk<Kl<!weOu!Htqg<gik!OliI?!kbqi<!
Osi<g<gUl</!
5/ Ljtgm<ce!kieqbl<?!hbqX!uqjkgt<?!hs<jsg<!gib<gxq?!gQjvgt<?!hiz<?!
hpl<?!ou{<o{b<?!ofb<!Osi<f<k!d{Ugt<?!sqxh<hig!ngk<kqg<gQjv?!
l{k<kg<gitqg<gQjv?!ouf<kbg<gQjv?!ohie<eir<gi{qg<gQjv?!nk<kqg<gib<?!
uijph<H,?!-tfQI?!Fr<G!-ux<jx!hbe<hMk<kzil</!
6/ oum<cOui<?!uqzilqs<SOui<?!fe<eiiq!Dxz<!GcfQjvBl<!upr<gzil</!
! !
.!hqt<jth<hq{q!lVk<Kul<!higl<!< < < < << < < < << < < < < .2?!h/w{</28<<< !
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MODERN ASPECTS 
APHTHOUS STOMATITIS 
 
 Aphthous stomatitis also known as recurrent aphthous ulcers or canker sores. 
The term aphthous is derived from a Greek word “aphtha” which means ulceration. 
aphthous stomatitis consists of solitary or multiple painful ulcerations occur on the 
Labial, buccal, lingual, sublingual, palatal or gingival mucosa. Lesions may manifest 
initially as erythematous, indurated papules that erode rapidly to form sharply 
circumscribed necrotic ulcers with a gray fibrinous exudate and an erythematous halo. 
 
ETIOLOGY 
1. TRAUMA: 
 Trauma to the oral mucosa due to Local anesthetic injections, sharp tooth, 
dental treatments and tooth brush injury may redispose to the development of 
recurrent aphthous ulcertation. 
 
2. MEDICATIONS: 
 Certain drugs have been associated with development of recurrent aphthous 
ulceration, these include angiotensin converting enzyme inhibitor, and NSAIDS, may 
also cause oral ulceration. 
 
3. HEMATINIC DEFIENCY: 
 Deficiencies of Iron, Vitamin B12, and folic acid predispose development of 
Aphthous stomatitis. 
 
4. INFECTIONS: 
 Viral, bacterial, treponemal and fungal agents have the potential to cause 
mouth ulcers. 
 
5. ALLERGY: 
 Sodium Lauryl sulfate present in toothpaste and oral hygiene products. 
 Foods such as coffee, chocolate, cheese, and citrus fruits. 
 toxin exposure (nitrates in drinking water) 
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6. GLUTEN SENSITIVE ENTEROPATHY / CELIAC DISEASE,     
    INFLAMMATORY BOWEL DISEASE: 
 Gluten sensitive enteropathy is an autoimmune inflammatory disease of small 
intestine of gluten, a wheat protein in susceptible individuals.  
 It is characterized by severe malnutrition, anemia, abdominal pain, glossititis 
and stomatitis. Aphthous stomatitis may be the sole manifestation of the 
disease. 
 The use of gluten - free diet in the improvement of Aphthous stomatitis is 
considered ulcertain. It has been suggested that evaluation for celiac disease 
may be appropriate for Aphthous stomatitis patients. Inflammatory bowel 
diseases such as crohn’s disease and ulcerative colitis may present with 
aphthous like ulceration. 
 
7. STRESS: 
 Stress has been emphasized as a causative factor in Aphthous ulcertation. It 
has been proposed that stress may induce trauma to oral soft tissues by para 
functional habits such as lip or cheek biting and this trauma may predispose to 
ulceration. 
 A more recent study shows lack of direct correlation between levels of stress 
and severity of aphthous stomatitis episodes and suggests that psychological 
stress may act as a triggering or modifying factor rather than etiological factor 
in susceptible Aphthous stomatitis patients. 
 
SIGNS AND SYMPTOMS: 
 Ulcers in the mouth, usually inside the lips, on the cheeks or on the tongue. 
 Ulcers that are covered with a yellow layer and have a red base 
 Fever 
 Burning sensation in the ulcer area. 
 painful ulcer. 
 Ceivical lymphadenopahty 
 Irritation of the sores by spicy or sour foods. 
 Loss of appitide. 
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TYPES: 
 Aphthous stomatitis has been classified based on the size and evolution of 
lesions into 3 types. 
1. minor aphthae 
2. major aphthae 
3. herpetiform ulcertations. 
 
1. Minor Aphthae: 
 Minor Aphthous stomatitis is also known as Miculiz’s aphthae or mild 
Aphthous ulcers. 
 It is the most common type of ulcer. 
 Ulcers vary from 2-10mm in size. 
 It is most commonly seen in the nonkeratinized mucosal surfaces like labial 
mucosa, buccal mucosa and floor of the mouth. 
 Ulcers heal within 7-10 days without scarring. 
 
2. Major Aphthae: 
 It also known as periodenitis mucosa necrotica recurrens or sutton’s disease. 
 It affects about 10-15% of patients.  
 Ulcers size - >10mm in diameter. 
 Most common sites of involvement are lips, soft palate, and fauces. 
Masticatory, mucosa like dorsum of tongue or gingiva may be occasionally 
involved. 
 To heal from 10-30 days, with scarring. 
 
3. Herpetiform ulceration: 
 Its characterized by recurrent craps of multiple ulcers. 
 These are small in size, measure 1-2 mm in diameter. 
 Most common sites of floor of mouth, palate, pharynx, gingiva. 
 Lesions which tent to coalesce into plaques and heal over 7-10 days. 
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PATHOPHYSIOLOGY: 
 Aphthous stomatitis are initially and primarily the result of T cell mediated 
immune dysfunction but also may involve neutrophil and mast cell mediated 
destruction of the mucosal ephtielium. Lesions can have alterations in several inter 
cellular mediators, such as elevations in interferon gamma, tumor necrosis factor - 
alpha and interleukins (IL)-2, IL-4, IL-5 as well as various adhersion molecules 
involved in cell communication and ephithelial integrity. This inflammatory process 
results in a psueomembrane contains fibrinous exudate, bacteria, inflammatory cells 
and necrotic mucosal cells. 
 Aphthous    stomatitis occur on no-keratinized oral mucosae such as along the 
labial or buccal surfaces, soft palate, the floor of the mouth, the ventral or lateral 
surface of the tongue, tonsillar fauces, free (marginal or unattached) gingiva adjacent 
to teeth, and alveolar gingiva  in the maxillary and mandibular sulci. 
 In contrast, ulcerations from herpes simplex virus involve the keratinized 
mucosal surfaces such as the attached gingival and dorsum of the tongue, lips and 
hard palate. 
 
INVESTIGATION: 
 The diagnosis of Aphthous stomatitis & usually based on the history and 
clinical presentation. No Laboratory procedures are available for definitive 
diagnosis. 
 In patients with severe recurrent aphthous ulcers. The clinical picture should 
guide laboratory testing. 
 CBC count, a chemistry, panel and nutricional workup may be necessary. 
 Patients with suspected malabsorption or a nutritional deficiency should 
undergo immediate screening, consider screening in patients presenting with a 
history of recurrent aphthous ulcers lasting 6 months or longer. 
 
TREATMENT: 
 Treatment of Aphthous stomatitis is palliative. 
 The majority of mild cases do not require therapy. 
 Relief of pain, particularly before eating, may be achieved with the use of a 
topical anesthetic such as viscous lidocaine or an oral rinse with a combined 
solution of elixir of diphonhydromine, viscous lidocaine, and an oral antacid. 
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 Caution must be taken to avoid hot food and drink after topical anesthetic use. 
 A superpotent topical corticosteroid in a mucosa-adhering agent may help 
reduce inflammation. 
 Topical tetracycline mouth wash may also hasten healing. 
 In severe, debilitating cases, systemic therapy with corticosteroids, colchicine, 
dapsone or thalidomine may be helpful. 
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4 . MATERIALS AND METHODS 
 
 The study on clinical evaluation of the disease ULL AKKARAM  with the 
trial drug POOVARASU ENNAI  was carried out on post graduate kuzhanthai  
maruthuvam department at  Government Siddha Medical College, Palayamkottai. 
 
SCREENING OF PATIENTS: 
 Out of 50 cases, randomly, The author selected 20 cases from OP and 20 cases 
from IP to my study. 20 patient of both male and female children were selected for the 
studies and admitted in post graduate kuzhanthai maruthuvam in patients ward for 
minimum 7 - 14 days and advised for further follow up as In- patients. 
 Another 20 patients were treated with trial drug in the out patients department 
in kuzhanthai maruthuvam. 
 
SELECTION OF PATIENTS: 
 The present study covers both male and female children of pediatric age 
groups. All cases were carefully examined before admission. Those who fulfilled the 
carried of “ULL AKKARAM ” according to the clinical features in siddha and 
Modern reviews were selected with the aid of questionnaire. 
 
STUDY PARTICIPANTS 
INCLUSION CRITERIA: 
 Age : 3 - 12 years 
 Sex : Both male and female children 
 Ulcer in Oral Cavity 
 Coated tongue 
 Fever 
 Running nose 
 Pallor 
 Polydipsia 
 
EXCLUSION CRITERIA: 
 Ca  Check 
 Ariboflavinosis 
 Chemical burns 
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 Herpetic gingivo stomatitis 
 Traumatic ulcer 
 Heat burns 
 Secondary syphilitic ulcer 
 
WITHDRAWAL CRITERIA: 
 If any adverse reactions & altered symptoms occurred during the drug trial. 
 Intolerance to the drug. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness. 
 
ASSESSMENT AND INVESTIGATIONS: 
 Clinical assessment 
 Siddha assessment 
 Laboratory investigations 
 
CLINICAL ASSESSMENT 
 Ulcer in oral cavity 
 Coated tongue 
 Fever 
 Running Nose 
 Pallor 
 Polydypsia 
 
  SIDDHA METHODOLOGY OF ASSESSMENT 
a) Nilam 
b) Kalam 
c) Uyir thathukkal 
d) Udal thathukkal 
c) Envagai thervugal 
• Naadi 
• Sparism 
• Naa 
• Niram 
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• Mozhi 
• Vizhi 
• Malam 
• Moothiram - Neerkuri, Neikkuri 
 
LABORATORY INVESTIGATIONS 
ROUTINE INVESTIGATION: 
I.BLOOD 
 TC 
 DC 
 ESR,  
 Hb% 
II. URINE 
 Albumin 
 Sugar 
 Deposits 
SPECIFIC INVESTIGATIONS 
• Pus culture from the ulcer 
DIETARY ADVICE: 
• Well nourished diet 
• Avoid spicy food 
• Avoid carbonated drinks 
• Good oral hygiene 
METHODOLOGY OF TREATMENT 
STUDY ENROLMENT 
  In this study, patients reporting at the OPD with the clinical symptoms of  
 Ulcer in oral cavity 
 Coated tongue 
 Fever 
 Running nose 
 Pallor 
 Polydypsia 
Patient will be examined clinically for enrolling in the study based on 
inclusion and exclusion criteria. 
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 The patients parent/ guardian who are to be enrolled patients would be 
informed (Form IV) about the study, trial drug, possible outcomes and the 
objectives of the study in the language and terms understandable to them 
and to their informants. 
 After ascertaining the parent’s willingness, informed consent would be 
obtained in writing from them in the consent form (Form IV-A). 
 All these patients Parent/ guardian will be given unique registration card in 
which patient’s registration number of the study address, phone number 
and Doctor’s phone number etc. will be given , So as to report easily if any 
complications arise. 
 Complete clinical history, complications and duration, examination 
findings and Laboratory investigation all would be recorded in the 
prescribed proforma in the history and clinical assessment forms 
separately. Screening form -I will be filled up; Form 1-A, Form II and 
Form III will be used for recording the patirnt’s history, clinical 
examination of symptoms, signs and laboratory investigations 
respectively. 
 Patients would be advised to take the trial drug and appropriate dietary 
advice (Form IV-D) would be given according to the patient’s perfect 
understanding.  
 
PROGNOSTIC CRITERIA 
GRADE I : Complete cure of symptoms of ULL AKKARAM     
 showed good improvement. 
GRADE II : Symptoms moderately reduced 
GRADE III : symptoms slightly reduced 
GRADE IV : Poor Response 
 
ADVERSE EFFECT/ SERIOUS EFFECT MANAGEMENT: 
 If the trial patient develops any adverse reactions, he/she would be withdrawn 
immediately from the trial and proper managements will be given to the patient. 
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ETHICAL ISSUES: 
• Informed consent will be obtained from the patient’s parent after explaining  
about the clinical trial in their understandable language. 
• After the consent of the patients parent (Through consent form) if they fit in 
the criteria, they will enrolled in the study. 
• Concomitant medicines will be used if the there is any ned. 
• There will be no infringements on the rights of the patients. 
• Treatment would be provided at free of cost. 
• The data collected from the  patient will be kept confidential, 
• In case of any adverse reactions the patients will be give rescue medications. 
• To prevent any infection while collection blood samples from the patients only 
disposable syringes, disposable gloves, with proper sterilization of laboratory 
equipment’s will be used. 
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PREPARATION OF TRIAL MEDICINE AND DRUG REVIEW 
PREPARATION OF TRIAL DRUG 
H,uvS!w{<o{b<< << << <!
. Nkivl<!;!!hqt<jth<hq{q!lVk<Kul<!)higl<!2*!!h/w{<!;!8?!< < < < < < << < < < < < << < < < < < <
lV/n/Sf<kvvi\e<?!< << << < B.I.M.,!
!
Osvl<!svg<Ggt<;< < << < << < < !
!! H,uvS!-jz!! ;! 22/8!gqvil<!
! h,uvS!H,! ! ;! 22/8!gqvil<!
! H,uvS!gib<! ! ;! 22/8!gqvil<!
! sikqg<gib<! ! ;! 3!gqvil<!
! sikqhk<kqiq! ! ;! 3!gqvil<!
! Wzg<gib<! ! ;! 3!gqvil<!
! Nl{g<G!w{<o{b<!;! 391!ml 
 
Ljx;!
!! gib<s<sq!uck<K!wMk<Kg<!ogit<tz<!
!
osb<Ljx;<<< !
H,uvS!-jz?!H,?!gib<!&e<jxBl<!keqk<keqbig!njvk<K!wMk<K!ye<X!
%m<c! njm! km<c/! ! sqx<xil{g<G! ofb<bqz<! gib<s<sq?! njm! squf<K! lqkg<Gl<!
OhiK!njmjb!fQg<gq!uqm<M?!!Wzl<?!!sikqg<gib<?!sikqhk<kqiq!Ngqb!&e<jxBl<!
wMk<K!ohick<Kg<!gzg<gq!gib<s<sq!wMk<K!ogit<t!Ou{<Ml</!
!
kQVl<!Ofib<;Q < <Q < <Q < < !
!! ns<svl<?!!gib<s<sz<!
!
NBm<gizl<;< << << < !
!! 7!likr<gt<!
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5. DRUG REVIEW 
2/H,uvS!
! Botanical name : Thespesia populnea 
 Family  : Malvaceae 
 Parts used  : -jz?!H,?!gib<?!hm<jm?!Oui<!
! Sju! ! ! ;! jgh<H?!Kui<h<H!
! ke<jl<<< ! ! ;! ouh<hl<!
! hqiqU! ! ! ;! giIh<H!
!
osb<jg<<< !
 HPg<ogiz<zq!
 K~b<jlbig<gq!
 dvlig<gq!
!
Chemical constituents 
 Four naturally occurring quinies viz. thespone, manosone-d, mansonone-H, 
thespone and thespesone have also been extracted from heartwood, Manosone, T-
hydroxy-2, 3, 4, 6-tetrahydro-3, 6, 9-trimethylnaphtho, pyran-4, 8-dione, mansonones 
D, E and F were isolated from stem. 
 
G{l<<<<!
! F~xi{<M!ose<xokiM!F~{<H,!uvsl<Oui<!
! K~x{<m!Gm<jmk<!okijzg<Gr<gi{<!.!uQxqh<!
! hPk<k-jz!uqjkH,hm<jmbqju!g{<mix<!
! HPk<kH{<uq!OvseLl<!Ohil<!
! Gm<mr<!gc$jz!ogiz<Zl<!uqmhigf<!
! Km<m!lOgikvLR<!OsijhObiM!–!gqm<colbqz<!
kiUgvh<!hie<gqvf<kq!k{<Olgl<!Ohig<gquqMl<!
! H,uvsr<!gib<ghm<jmh<H,!
!
 F~xi{<M!ose<x!H,uvsl<!Oui<?!fim<hm<m!ohVOfijb!fQg<Gl</!!hPh<hqjz?!
H,?!uqjk?!gib<?!hm<jm!Lkzqbju/!!hPk<k!H{<?!gi{ig<gc?!Gk<kz<?!
uqmhigl<?!ohVubqX?!uQg<gl<?!gvh<hie<?!sqvr<G?!out<jt!-jugjth<!
Ohig<Gl</!
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!
3/sikqg<gib<< << << <!
Botanical name : Myristica fragrans 
 Family  : Myristicaceae 
 Parts used  : gib<!
! Sju! ! ! ;! Kui<h<H?!giIh<H!
! ke<jl<<< ! ! ;! ouh<hl<!
! hqiqU! ! ! ;! giIh<H!
!
osb<jg<<< !
 ouh<hL{<mig<gq!
 ngm<Muib<ugx<xq!
 &Is<jsB{<mig<gq!
 l{&m<c!
 gill<ohVg<gq!
 dvlig<gq!
!
Chemical constituents 
 Beta pipene, Alpha Terpinene, Safrole, Methyl Eugenol, Myristicin, Elemicin, 
Trimyristin, Dihydro-disoeugeneol, Myristic acid, Epicatechin, cyanadin, Nectandrin 
B, verrucosin, lignans and neolignans etc. 
G{l<<<<!
! kiKfm<ml<!Ohkq!sVuisq!bR<sqvOfib<!
! YKSui!sr<gisl<!dm<gqvi{q!–!OuOki!
! czg<gib<!uVl<hq{qOhil<!Wx<xlbz<!hqk<kr<!
! Gzg<gi!bVf<Kui<g<Gg<!%X/!
 -keiz<!uqf<K!GjxU?!ohVr<gpqs<sz<?!uiBuqeiZ{<miGl<!Ofib<?!
kjzuzq?!-jvh<H?!-Vlz<?!fim<hm<m!gpqs<sz<?!ouh<hk<jk!Le<eqm<MuVl<!
hq{qgt<!ohiGl</!!Neiz<!lbg<gk<jkk<!kVl</!!OlZl<!-K!ubqx<Xuzq?!
ubqx<Xh<ohiVlz<?!ng<gqeq!lf<kl<!-jugjtBl<!Ohig<Gl</!
! !
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4/sikqhk<kqiq<<< !
Botanical name : Myristica fragrans 
 Family  : Myristicaceae 
 Parts used  : Dry mace 
! Sju! ! ! ;! giIh<H?!Kui<h<H!
! ke<jl<<< ! ! ;! ouh<hl<!
! hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 gill<!ohVg<gq!
 ngm<Muib<ugx<xq!
 ouh<hL{<mig<gq!
 dxg<gL{<mig<gq!
Chemical constituents 
 Mace contains 4-15% of volatile oil similar to nutmeg.  It contains all the 
other chemicals as described in oil of nutmeg it also contains fat. amylodextrin, 
myristicin etc. 
G{l<<<<!
! sikqkVl<!hk<kqiqg<Gk<!kihs<!Svf<k{qBl<!
! YKgqe<x!hqk<kl<!dbVr<gi{<!.!kiKuqi<k<kq!
B{<mir<!gqvg{qObi!Omikg<!gpqs<szXl<!
h{<mir<!GjxOb!hgi</!
 -keiz<!kihSvl<?!fq{Ohkq?!fQIg<gpqs<sz<!-ju!OhiGl</!!-K!
dmx<gm<Mgjt!uZg<gs<!osb<Bl</!!npjz!d{<mig<Gl</!
! !
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5/Wzl<<<<!
Botanical name : Elletaria cardamomum 
 Family  : Zingiberaceae 
 Parts used  : Dried ripe seeds, oil from frouits. 
! Sju! ! ! ;! giIh<H!
! ke<jl<<< ! ! ;! ouh<hl<!
! hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 ouh<hL{<mig<gq!
 ngm<Muib<ugx<xq!
 hsqk<kQk<K~{<c!
Chemical constituents 
 Fixed oil, essential oil, volatile oil of the seeds and contains a considerable 
amount of terpinyl acetate, cineole, free terpineol and probably also limonene are 
present.  In presence of α pinene, sabinene, myrcene, limonene, cineol, cymene, my 
heptenone, linalool, linalyl acetate, β terpineol, & terpineol, α terpiniyl acetate, 
borneal, neryl acetate, geraniol, nerol, neolidol, heptacosane and unidentified 
compounds 9.7% in essential oil 
G{l<<<<!
! oki{<jm!uib<gUt<!kiZg!kr<gtqz<!
! ! Okie<Xl<!Ofibkq!sivl<he<!Olgk<kiz<!
! d{<jm!Ohiz<!wPr<!gm<c!gqiqs<svl<!
! ! dpjz!uif<kq!sqzf<kq!uq]R<Svl<!
h{<jm!oug<jg!uqkigOfib<!gisLl<!
! ! hiPR<!Osilh<!hq{quqf<K!fm<mLl<!
n{<jm!bQjtue<!hqk<kl<!-jug<ogzil<!
! ! Nz!lir<glp<!Wz!lVf<kOk!
 -K!oki{<jm?!kit<?!uib<?!gQp<uib<!-jugtqz<!d{<miGl<!
Ofib<gjtBl<?!-Vlz<?!gpqs<sz<?!fQIs<SVg<G?!ofR<sqe<!Ogijpg<gm<M?!
sqzf<kq!fR<S!-jugjtBl<!Ohig<Gl</!!npjz!Nx<Xl</!!ou{<{Qjvh<!
ohVg<Gl</!
! !
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6/Nl{g<G<<< !
Botanical name : Ricinus communis 
 Family  : Euphorbiaceae 
 Parts used  : Oil, leaves, roots and seeds 
! Sju! ! ! ;! jgh<H!
! ke<jl<<< ! ! ;! ouh<hl<!
! hqiqU! ! ! ;! gii<h<H!
osb<jg<<< !
 lzlqtg<gq!
 uxm<sqbgx<xq!
Chemical constituents 
 The seeds contain 45% of fixed oil which consists glycerides, ricinoleic, 
stearic, dihydroxystearic acids, lipases and alkaloid ricinine. 
G{l<<<<!
! Nl{g<G!ofb<biz<!fzL{<mil<!biui<g<Gl<!
! H,l{g<G!Oleq!HiqGpOz!–!uib<l{g<gg<!
! ogit<tqz<!ubqX!uqMr<!OgivLt<t!uiBuXl<!!
dt<tqz<uV!Ge<ll<Ohi!OliK!
!
nl<ohieqx!Ll<uqf<K!lir<Gmzq!Oex<xlXl<!
Jl<ohixqs<!$omiqU!liXr<gi{<!nl<Huqbx<!
hil{g<G!lqe<holipqh<!hiuib<"!fzR<osxqf<k!
Nl{g<G!ofb<jb!bVf<K/!
!
Nl{g<!og{<o{b<!ke<je!b{qfqz!lxqbg<!Og{<lqe<!
H,l{s<!sf<K!OkiXl<!ohiVf<kqb!uikl<!Ohig<Gl</!
kQlf<kf<!kiEl<!Ohig<Gf<!kqgp<Ume<!uqjvUL{<mil<!
kQleg<!Gmzqz<!uikR<!Osi<Gm!Ozx<xl<!OhiOl!
!
 -K!lVf<kqe<!Ougl<?!uzqbqeiz<!wVuibqZ{<miGl<!npjz!)fQIs<SVg<G?!
out<jt*!Ngqbjugjt!fQg<Gl<!
 Gpf<jkgjtk<!kib<h<Ohiz<!uti<g<Gl<!
 -jkh<!Ohkqbiukx<Gg<!ogiMg<gzil</!
!
!
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!
!
 Gpf<jkgTg<Gl<?!hqt<jt!ohx<x!oh{<gTg<Gl<!ubqX!gpqbg<!
ogiMh<hkx<G!-0K!yV!sqxf<k!lVf<kiGl</!
 ubqx<Xuzq?!wVuib<!gMh<H!Lkzqbjugjth<!hqxh<hqbiK/!
 Njgbiz<!-jk!jgg<Gpf<jk?!gQp<ubKjmbui<?!$z<!ogi{<mui<?!
hqt<jt!ohx<xui<?!sQkGVkq!Ohkqbiz<!uVf<Khui<!Lkzqbui<gTg<Gl<!
ns<slqe<xqg<!ogiMg<gzil</!
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Fig. 1  INGREDIENTS OF POOVARASU ENNAI 
 
H,uvS!-jz!
(Thespesia populnea) 
!
H,uvS!lzi<<<<!!
(Thespesia populnea) 
H,uvS!gib<<<<!
(Thespesia populnea) 
sikqg<gib<< << << <!
(Myristica fragrans) 
Wzg<gib<< << << <!
(Elletaria cardamomum) 
sikqhk<kqiq<<< !
(Myristica fragrans) 
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!
  
Nl{g<G!w{<o{b<< < << < << < <!
(Ricinus communis) 
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!
!
!
!
Fig. 2  H,uvS!w{<o{b<< << << <!
!
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6. BIO-CHEMICAL ANALYSIS OF  POOVARASU ENNAI 
 
Preparation of the extract:   
   5gms of the drug was weighed accurately and placed in a 250 ml clean 
beaker.  Then 50ml of distilled water is added and dissolved well.  Then it is boiled 
well for about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and 
then it is make up to 100ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
No white precepitate 
is formed 
Absence of 
calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed 
Indicates the 
presence of 
sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
A white precipitate is 
formed 
Indicates the 
presence of 
chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No Brisk 
effervessence is 
formed 
Absence of 
carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour is 
formed 
Indicates the 
presence  of  
starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of 
Ferric iron 
7. TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cynate 
solution 
 
Blood red colour is 
formed 
Indicates the 
presence of 
ferrous Iron. 
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8.  TEST FOR PHOSPHATE 
The extract is treated with ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate is formed 
Absence of 
phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with Esbatch’s 
reagent 
No Yellow 
precipitate is formed 
Absence of 
Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with ferric 
choloride. 
No Blue black 
precipitate is formed 
Absence of 
Tannic acid 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets decolourised. 
Indicates the 
presence of   
unsaturated 
compound 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mins and add 8-10 drops of the extract 
and again boil it for 2 mins. 
No Colour change 
occurs. 
Absence of 
Reducing sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried well. 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
    The extract prepared from the given sample POOVARASU ENNAI contains 
sulphate, chloride, starch, ferrous iron, unsaturated compound and amino acid. Biochemical 
Analysis report was given by Mrs. N.Nagaprema, M.Sc., M.Phil., Head of the Department, 
Biochemical Department, Government Siddha Medical College, Palayamkottai. 
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7. PHARMACOLOGICAL ANALYSIS 
ANTIPYRETIC ACTIVITY OF POOVARASU ENNAI 
 
MATERIALS AND METHODS 
Experimental Animals  
  Wistar albino rats of either sex weighing about 150-200g were employed for 
this study. They were procured from Kalasalingam college of Pharmacy, srivilliputhur 
and maintained on the suitable nutritional and environmental condition throughout the 
experiment. They were housed in polypropylene cages with paddy house bedding 
under standard laboratory condition for an acclimatization periods of 7 days prior to 
performing the experiment. 
 
Experimental Design . 
Protocol 
  Body weights of the animals were recorded and they were randomly divided 
into 5 groups of 6 animals each as follows: 
Group I  :  animals served as control  
Group II  :   animals were treated with yeast via subcutaneous    
injection (10ml/kg).  
Group III  :   animals were administered with yeast (10 ml/kg) and ] 
the standard drug  paracetamol (150mg/kg b.w.), orally  
Group IV  :   animals were administered with yeast (10ml/kg,) and  
with PE (100mg/kg b.w.), orally.  
Group V  :   animals were administered with yeast (10ml/kg,) and  
with PE(200mg/kg b.w.), orally.   
Yeast induced pyrexia  
  Pyrexia was induced by subcutaneous injection of 20 % w/v of brewer’s yeast 
(10ml/kg) in distilled water. Basal rectal temperature was measured before the 
injection of yeast, by inserting digital clinical thermometer to a depth of 2 cm into the 
rectum.  
  The rise in rectal temperature was recorded 19 hrs after yeast injection. 
Paracetamol 150mg/kg body weight was used as the standard antipyretic drug. Rectal 
temperature of animals was noted at regular intervals following the respective 
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treatments.The temperature was measured at 1st, 2nd, and 3rd hour after drug 
administration. 
 
Statistical Significance  
  The statistical analysis was done by ANOVA followed by Dunnet’s test for 
multiple comparisons. P < 0.01 was considered significant in the experiment. 
 
Table1: Effect of aqueous and ethanol extracts of Poovarasu ennai on body 
temperature in   yeast induced pyrexia 
Groups Rectal Temperature in 0C after 18hrs of Yeast Injection 
 
0 hr 1hr 2hr 3hr 
Group I 37.40±0.06 37.95±0.02 37.50±0.72 37.62±0.41 
Group II 40.48±0.18 40.08±1.02 39.08±1.05 39.02±0.70 
Group III 40.18±0.23 42.02±0.18 38.45±0.28 37.50±0.18 
Group IV 40.62±0.17 39.72±0.18 39.02±0.18 38.18±0.18 
Group V 40.52±0.12 39.20±0.18 38.08±0.41 37.50±0.16 
 
Values are expressed as Mean ±SEM.   n = 6 in each group, “*” indicate P < 0.01 
compared to control 
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DISCUSSION 
  Fever is a complex physiologic response triggered by infections or aseptic 
stimuli. Elevation in body temperature occurs when the concentration of 
prostaglandin E2 (PGE2) increases within parts of the brain. Such an elevation 
contributes to a considerable alteration in the firing rate of neurons that control the 
thermoregulation process in the hypothalamus. It is now evident that most of the 
antipyretic drugs exert their action by inhibiting the enzymatic activity of 
cyclooxygenase and consequently reducing the levels of PGE2 within the 
hypothalamic region. A natural antipyretic agent with reduced or no toxicity is 
therefore, essential.  
  Since antipyretic activity is commonly mentioned as a characteristic of drugs 
or compounds, which have an inhibitory activity on prostaglandins biosynthesis, the 
yeast induced hyperpyrexia in rat model was employed to investigate the antipyretic 
activity of the extract. Yeast induced pyrexia is called pathogenic fever which is due 
to the production of prostaglandins (PGE2) which set the thermoregulatory centre at a 
higher temperature.   
  The HIGH DOSE PE showed more pronounced effect in lowering the 
hyperthermia than the LOW DOSE PE, but found to have similar effect as the 
standard drug Paracetamol at 3rd hour of administration. The extracts are likely to 
reduce pyrexia by reducing brain concentration of prostaglandin E2 especially in the 
hypothalamus through its action on COX-3 or by enhancement of the production of 
the body’s own antipyretic substances like vasopressin and arginine.   
  Antipyretics have been shown to suppress fever by inhibiting prostaglandin 
synthetase, resulting in the blockade of the synthesis of prostaglandin in the brain or 
suppressing the rise of interleukin1α production subsequent to interferon production . 
 
CONCLUSION  
  In conclusion, this study provides evidences for the antipyretic activity PE 
which could partly contribute to its ethno medical use. However, further investigation 
is required to isolate the active constituents responsible for these activities and to 
elucidate the exact mechanisms of action. 
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ANTI-INFLAMMATORY ACTIVITY OF POOVARASU ENNAI 
 
  The anti-inflammatory activities of Poovarasu Ennai  at 100 and 200 mg/kg 
doses were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such 
as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae) and when injected cause the release of prostaglandins by the way it 
produces inflammation and edema. 
 
REQUIREMENTS: 
Animal                                 :  Albino rat (180-200 g) 
Drugs and chemicals    :  Carrageenan (1%w/v),  
Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
 Plethysmo meter. 
Test compounds                :    Poovarasu Ennai   
 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the Poovarasu Ennai test Compounds 
dissolved with 2 ml sterile water given through orally 30 min before the carrageenan 
treatment. The paw volumes of the test compounds, standard and control groups were 
measured at 60,240,360 minutes of carrageenan treatment with the help of  
plethysmometer . Mean increase in paw volume was measured and the percentage of 
inhibition was calculated. 
 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
 Vc-mean increase in paw volume in control group of rats. 
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TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF POOVARASU ENNAI 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 10ml/kg orally 5.76±0.96 - 
Group II 
Std 
10mg/kg 
I.P.Diclofenac 
sodium 
2..26±0.40 60.76%*a 
Group III 
Poovarasu Ennai 
 
100mg/kg.Orally. 2.62±0.48 54.51%*a 
Group IV 
Poovarasu Ennai 
 
200mg/kg.Orally. 2.44±0.52 57.63%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
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Results 
Anti- inflammatory activity 
  Poovarasu Ennai  at 100 and 200 mg/kg doeses were tested for their Anti- 
inflammatory activity by using carrageenan Induced rat paw edema method and the 
results are tabulated in table no 1.  The results reveals that   both extracts of Poovarasu 
Ennai  at 100 and 200 mg/kg doses possesses significant Anti- inflammatory activity 
when compared to control group at p<0.01. 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF POOVARASU ENNAI 
Effect of Acute Toxicity Study (14 Days) of POOVARASU ENNAI 
Table no –12   Physical and behavioral examinations. 
Group no. Dose(mg/kg) Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
Table no-13    Home cage activity 
Functional 
and 
Behavioural 
observation 
Observation 
5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body 
position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
 57
Table no-14  Hand  held  observation 
Functional 
and 
Behavioral 
observation 
Observation 
Control 
5 mg/ 
kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
 n=3 
Female 
n=3 
Femal
e n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-15   Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
POOVARASU ENNAI at a dose of 2000 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 
POOVARASU ENNAI is 2000 mg/kg. 
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DISCUSSION 
  POOVARASU ENNAIwas administered single time at the dose of 5mg/kg, 
50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioural signs of any toxicity due 
to administration of POOVARASU ENNAIat the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
POOVARASU ENNAIon the growth rate. Body weight change in drug treated 
animals was found normal. 
 
INTERPRETATION: 
 POOVARASU ENNAIwas administered single time at the dose of 5mg/kg, 
50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behaviou ral signs of any toxicity due 
to administration of POOVARASU ENNAI at the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
 59
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
POOVARASU ENNAI on the growth rate. Body weight change in drug treated 
animals was found normal. 
  
 60
SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF POOVARASU ENNAI 
Table :16 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF POOVARASU 
ENNAI ON BODY WEIGHT IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
1st day 122.3±2.03 125±2.543 124.3±3.231 126.3±3.23 
7th day 132.3±2.03 131.3±2.343 131±3.113 137±3.11 
14th day 134.1±2.004 102.3±2.12 102.4±3.012 103.4±3.012 
21st day 103.3±3.120 110.2±2.501 104±2.131 105±2.13 
28th day 113.3±2.041 112.3±2.202 143±3.0405 146±3.040 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
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EFFECT OF SUBACUTE DOSE (28 DAYS)OF POOVARASU ENNAI 
ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
HEART 1.43±1.02 1.24±1.04 1.01±1.11 0.91±1.02 
LIVER 2.31± 1.23 1.33±1.23 2.20±1.01 2.23± 1.23 
LUNGS 1.31±1.10 0.31±1.14 0.50±1.24 1.43±1.10 
KIDNEY L 0.43±1.02 1.52±1.03 0.43±1.02 0.41±1.02 
 R 0.41±1.024 1.14±1.02 0.41±1.024 0.42±1.024 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF POOVARASU ENNAI ON 
HAEMATOLOGICAL PARAMETERS 
Table no 18 
Drug 
treatme
nt 
RBC 
million 
cells/cm
m 
WBC  
cells/cmm 
Haemogl
obin gm 
% 
Differential count % 
Neutop
hils 
Eosinop
hils 
Monoc
yte 
Limpoc
yte 
Control 5.21±01.
40 
7252.41±2
4.32 
14.40±1.4
5 
31.27±2
.20 
4.53±1.1
1 
o.45±1.
15 
23.13±4
.32 
LOW  6.47±1.2
0 
334.04±24
.22 
14.20±1.4
3 
25.54±2
.41 
2.10±1.1
4 
0.62±1
30 
23.22±4
.51 
MID 5.33±1.2
1 
5304.25±3
3.35 
14.11±2.0
3 
30.32±3
.22 
5.44±1.1
2 
0.52±1.
40 
23.13±4
.32 
HIGH 5.26±1.2
1 
6688.25±3
3.35 
16.11±2.0
3 
28.32±3
.22 
4.50±1.1
2 
0.54±1.
40 
24.13±4
.32 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table :19  EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF POOVARASU 
ENNAI ON BIOCHEMICAL PARAMETERS 
 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 42.14±4.02 13.24±5.31 243.12±12.32 36.35±4.00 0.54±1.03 
LOW 42.13±4.22 11.23±5.01 251.11±13.42 41.53±3.42 0.30±1.04 
MID 40.21±5.44 14.31±3.21 245.45±5.14 37.12±3.22 0.55±1.04 
HIGH 42.21±5.44 10.31±3.21 234.45±5.14 39.12±3.22 0.66±1.04 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF POOVARASU ENNAI 
BIOCHEMICAL PARAMETERS 
 
GROUP CONTROL PE 
(200mg/kg) 
PE 
(400mg/kg) 
PE 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
0.8±0.24 1.058±0.27 0.88±0.36 0.904±0.1 
  
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table:21 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF POOVARASU 
ENNAI ON FOOD INTAKE IN GRAM 
 
GROUP CONTROL low mid high 
1st DAY 18.33±14.5110 19.1672±15.3 12.10±22.71 17.5±8.62 
7th DAY 15.5±12. 10.863±13.67 16.73±10.853 11.17±15.41 
14th DAY 18.83±9.72 10.83±15.28 10±14.96 19.72±9.981 
21st DAY 11.87±13.4 15±9.466 15.88±10.43 19.17±9.02 
28th DAY 12.10±12.38 18.38±12.50 10±9.90 10±8.57 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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TABLE:22. EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF  POOVARASU 
ENNAI ON WATER INTAKE IN ML 
GROUP CONTROL PE 
(200mg/kg) 
PE 
(400mg/kg) 
PE 
(600mg/kg) 
1st DAY 98.3338±13.5110 89.1672±14.3426 102.10±21.7199 67.5±7.6203 
7th DAY 85.5±11.7938 100.863±12.6770 76.6673±9.85363 81.6717±14.410 
14th DAY 58.3383±8.72817 90.8363±14.2812 80±13.9692 89.1672±8.88981 
21st DAY 91.6687±12.4949 85±8.46662 65.8338±9.43550 89.1717±8.79602 
28th DAY 82.10±11.3840 88.3348±11.5004 80±8.90061 70±7.57773 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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Table: 23  EFFECT OF SUB ACUTE DOSES (28 DAY) OF POOVARASU 
ENNAI ON ELECTROLYTES: - 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001,  
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GROUP CONTROL 
PE 
(200mg/kg) 
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(400mg/kg) 
PE 
(600mg/kg) 
Sodium (mg/dl) 
154.10±0.65 134.30±0.92 121±0.7571 131.80±0.70 
Calcium(mg/dl) 7.50±0.139 5.20±0.175783*** 6.7±0.169 6.180±0.19611*** 
Phosphorus 
(U/L) 6.278±0.023017 5.3010±0.019915ns 5..35630±0.035491ns 5.037±0.32502* 
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6.0 RESULTS: 
CLINICAL SIGNS: 
  All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
  All animals in control and in all the treated dose groups survived 
throughout the dosing period of 28 days. 
   Body weight: 
Results of body weight determination of animals from control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 
days. 
Food consumption: 
  During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
  Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective 
control animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
  The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
  Results of Biochemical investigations conducted on the day 29th and 
recorded in Table no 24, 25 revealed the following significant changes in the values 
of hepatic serum enzymes studied. When compared with those of respective 
control. However, the increase or decrease in the values obtained was within 
normal biological and laboratory limits. 
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INTERPRETATION: 
1) All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2) No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28 days 
5) Haematological analysis conducted at the end of the dosing period on day 
29th, revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, 
no abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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8. ANTIMICROBIAL STUDIES 
Aim 
 To study the Anti-microbial action of “Poovarasu Ennai” against  
Staphylococcus aureus, pseudomonas aeruginosae, escherichia coli. 
 
Medium 
Mueller Hinton agar. 
Components of medium  
Beef extract   - 300gms/lit 
Agar    - 17 gms/lit 
Starch    - 1.5 gms/lit 
Casein Hydroxylate  - 17.5 gms/lit 
Distilled water  - 1000 ml 
PH    - 7.6 
Procedure 
 The media was prepared from the above components and poured and dried on 
a petri dish. The organism was streaked on the medium and the test drug (1gm drug in 
10ml of water) was placed on the medium. This is incubated at 37°C for one over 
night and observed for the susceptibility shown up clearance around the drug. 
 
Result: 
  The test drug Poovarasu Ennai was sensitive against  Staphylococcus aureus. 
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Fig. 3  ANTI MICROBIAL STUDY OF POOVARASU ENNAI 
 
Staphylococcus aureus 
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9.OBSERVATIONS AND RESULTS 
 
Results were observe with respect to the following criteria 
1. Age 
2. Sex 
3. Religion 
4. Economic status of the patient 
5. Etiology 
6. Diet  
7. Paruvakaalam 
8. Distribution of land 
9. Mode of onset 
10. Clinical features of Ull Akkaram during admission 
11. Tridosha theory 
12. Ezhu udarkattugal 
13. Envagai thervugal  
14. Neerkuri, Neikuri 
15. Out-patient record 
16. In-patient case sheet reports 
17. Laboratory Investigation 
18. Results after treatment 
19. Results accoding to age criteria after treatment 
 
  20 Out patients and 20 In-patients were selected for this observational study 
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Table : 1 . AGE REFERENCE 
 
S.No. Age Number of cases 
(Out of 40) 
Percentage (%) 
1 3 – 7 years 14 35 
2 7 – 12 years 26 65 
 
 
 
Inference 
 The percentage was highest in the age group of 7 – 12 years, the percentage 
was 65 %, between the age of  3 – 7 years, the percentage was  35%. 
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Table : 2. SEX REFERENCE 
 
S.No. Sex Number of cases 
(Out of 40) 
Percentage (%) 
1 Male Children 19 47.5 
2 Female Children 21 52.5 
 
 
Inference: 
 Out of the 40 patients, 47.5%  of cases were Male children and 52.5% were 
Female children. 
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Table : 3. RELIGION REFERENCE 
 
S.No. Religion Number of cases 
(Out of 40) 
Percentage (%) 
1. Hindu 34 85 
2. Christian 3 7.5 
3. Muslim 3 7.5 
 
B 
Inference: 
 In 40 of cases, 85% of cases were Hindu, 7.5 % were Christian, 7.5% were 
Muslim. 
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Table : 4. SOCIO ECONOMIC STATUS  
 
 
Inference: 
 Out of 40 patients, 70% of cases were Middle,  30% of cases were Lower 
income groups.   
  
30
70
0
0
10
20
30
40
50
60
70
80
Lower income groups Middle income groups High income groups
Pe
rc
e
n
ta
ge
 
(%
)
Cases
S.No. Socio economic status 
Number of cases 
(Out of 40) Percentage (%) 
1 Lower income groups 12 30 
2 Middle income groups 28 70 
3. High income groups - - 
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Table : 5. ETIOLOGY REFERENCE   
 
S.No. Etiology 
Number of cases 
(Out of 40) Percentage (%) 
1 Trauma 4 10 
2 Medications 6 15 
3 Infections 4 10 
4 Allergy 4 10 
5 Hematinic deficiency 2 5 
6 Others(spicy foods, climate, 
unknown) 
20 50 
 
 
 
Inference : 
  Out of 40 patients, Trauma, infections, allergy was seen in 10% of cases, 
medications was seen in 15% of cases, hematinic deficiency was seen in 5% of cases, 
others was seen in 50% of cases. 
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Table : 6. DIET REFERENCE 
 
 
 
 
Inference: 
 
 Out of 40 patients 80% of cases were Mixed diet and 20% of cases were 
Vegetarian. 
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S.No. Diet habit Number of cases 
(Out of 40) 
Percentage (%) 
1 Vegetarian 8 20 
2 Mixed diet 32 80 
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Table : 7. PARUVAKAALAM 
S.No. Paruvakaalam Number of cases 
(Out of 40) 
Percentage (%) 
1. Kaarkaalam (Aavani & Puratasi) 12 30 
2. Koothirkaalam (Ayppasi & Karthigai) 2 5 
3. Munpanikaalam (Markazhi & Thai) 8 20 
4. Pinpanikaalam (Maasi & Panguni) 13 32.5 
5. Elavenilkaalam (Chithirai & Vaikaasi) 5 12.5 
6. Muthuvenilkaalam (Aavani & Aadi) 0 0 
 
 
 
Inference : 
 According to Paruvakaalam high incidence of 32.5% of cases in Pinpani 
kaalam  30% of cases in Kaarkaalam, 20% cases in Munpanikaalam, 12.5% of cases 
in Elavenil Kaalam and 5% cases in Koothirkaalam. 
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Table : 8. DISTRIBUTION OF LAND 
 
 
 
 
Inference: 
 Out of 40 patients, 87.5% of cases belongs to Marutham and 12.5% of cases 
belongs to Neithal. 
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S.No. Thinai 
Number of cases 
(Out of 40) Percentage 
1 Kurinji (Hill) - - 
2 Mullai (Forest) - - 
3 Marutham (Fertile) 35 87.5 
4 Neithal (Coastal) 5 12.5 
5 Paalai (Desert) - - 
 86
 
Table : 9. MODE OF ONSET 
 
 
 
 
Inference: 
  Out of 40 patients 100% of cases had Acute onset of symptoms.  
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S.No. Mode of onset Number of cases 
(Out of 40) 
Percentage (%) 
1 Acute 40 100 
2 Chronic - - 
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Table : 10. CLINICAL FEATURES REFERENCE 
 
S.No. Clinical features Number of cases 
(Out of 40) 
Percentage 
1 Ulcer in buccal mucosa 18 45 
2 Ulcer in lips 19 47.5 
3 Ulcer in tongue 8 20 
4 Coated tongue 8 20 
5 Fever 6 15 
6 Pallor 8 20 
7 Running nose  5 12.5 
8 Polydipsia - - 
9 Cervical 
lymphadenopathy 
11 27.5 
 
 
Inference: 
  Among 40 cases 45 % of the patients had ulcer in buccal mucosa, 47.5% of 
the patients had ulcer in lips, 20% of the patients had ulcer in tongue, coated tongue 
and pallor, 12.5% of the patients had running nose, 15% of the patients had fever, 
27.5% of the patients had cervical lymphadenopathy. 
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Table : 11. TRIDOSHA REFERENCE 
 
DERANGEMENT OF  VATHAM 
 
 
 
 
Inference 
 According to Vatham, derangement of Uthanan was  100% ,  derangement of  
Kirukaran was 40%. 
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S.No. Classification of Vatham Number of cases 
(Out of 40) 
Percentage (%) 
1 Piranan - - 
2 Abaanan - - 
3 Viyanan - - 
4 Uthanan 40 100 
5 Samaanan - - 
6 Naagan - - 
7 Koorman - - 
8 Kirukaran 16 40 
9 Devathathan - - 
10 Thananjeyan - - 
 89
DERANGEMENT OF  PITHAM 
 
S.No. Classification of Pitham Number of cases 
(Out of 40) 
Percentage (%) 
1 Anal pitham 40 100 
2 Ranjagam 20 50 
3 Prasagam - - 
4 Sathagam  20 50 
5 Alosagam - - 
  
 
 
Inference : 
 According to Pitham, derangement of Anarpitham was 100%, derangement of 
Ranjagam was 50%, derangement of Saathagam was 50% of cases. 
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DERANGEMENT OF  KABAM 
 
 
 
 
Inference: 
 According to  Kabam, derangement of Kilethagam was 100%,  Pothagam was 
40%. 
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S.No. Classification of Kabam Number of cases 
(Out of 40) 
Percentage (%) 
1 Avalambagam - - 
2 Kilethagam 40 100 
3 Pothagam 16 40 
4 Tharpagam - - 
5 Santhigam - - 
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Table : 12. EZHU UDARKATTUGAL REFERENCE 
 
 
 
Inference : 
 Saaram, Oon was affected in in 100% of cases and Seneer was affected in 
50% of cases. 
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S.No. Ezhu udarkattugal 
Number of cases 
(Out of 40) Percentage (%) 
1 Saaram 40 100 
2 Senneer 20 50 
3 Oon 40 100 
4 Kozhuppu - - 
5 Enbu - - 
6 Moolai - - 
7 Sukkilam/Suronitham - - 
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Table : 13. ENVAGAI THERVUGAL  
 
 
 
 
Inference: 
 In Naadi, Pitha kabam was observed in 75% of cases, Pitha vaatham  was 
observed in 25% of cases, Naa was affected in 40% of cases, Niram was affected in 
20% of cases, mozhi was affected in 15% of cases, Sparisam was affected in 15% of 
cases. 
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S.No. Envagai thervugal 
Number of cases 
(Out of 40) Percentage 
1 Naadi   
         a.   Pitha kabam 30 75 
         b. Pitha vaatham 10 25 
2 Sparisam  6 15 
3 Naa 16 40 
4 Niram 8 20 
5 Mozhi 6 15 
6 Vizhi  8 20 
7 Malam - - 
8 Moothiram - - 
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Table : 14. NEERKURI , NEIKURI REFERENCE 
 
NEERKURI 
 
 
 
 
Inference: 
 Neerkuri was observed in 100% of cases. 
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S.No. Neerkuri 
Number of cases 
(Out of 40) 
Percentage 
1 Neerkuri 40 100 
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NEIKURI  
 
S.No. Neikuri 
Number of cases 
(Out of 40) 
Percentage 
1 Vatha neer  (Spreads like serpent) 2 5 
2. Pitha neer    (Spreads like ring) 36 90 
3. Kaba neer   (Spreads like pearl) 2 5 
 
 
 
Inference: 
 According to Neikuri, Pitha neer was observed in 90 % of cases, Vatha neer 
was observed in 5% of cases, Kaba neer was observed in 5% of cases. 
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Table : 15  OUT PATIENT RECORD 
S.No Op.No. Name Age /Sex 
No. of  
days treated 
Remarks 
1. 69466 Kanishka 5FC 14 days Good 
2. 69897 Raja 8MC 14 days Good 
3. 74364 Amutha 12FC 14 days Good 
4. 76795 Rakshin 6MC 14 days Good 
5. 79240 Dharshini 3FC 14 days Good 
6. 79535 Thillai yakshara 10FC 14 days Good 
7. 79900 Balahari 5FC 14 days Good 
8. 80067 Rakshitha 5FC 14 days Good 
9. 80388 Vishnu sangar 12MC 14 days Moderate 
10. 80725 Malathi 11FC 14 days Good 
11. 80784 Siranjeevi 12MC 14 days Moderate 
12. 82758 Balahariharan 6MC 14 days Good 
13. 96684 Amutha 12FC 14 days Good 
14. 101211 Sarkuna 11MC 14 days Moderate 
15. 102971 Yakshara 10FC 14 days Good 
16. 105567 Dharun raj 11MC 14 days Good 
17. 108618 Lavanya 10FC   14 days Good 
18. 701 Sivashankari 12FC 14 days Good 
19. 2187 Jayanthi 12FC   14 days Moderate 
20. 16876 Auisha 12FC 14 days Good 
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Table : 16 INPATIENTS CASE SHEET REPORTS 
S.No IP No Name of patient Age/sex 
Duration 
of illness Signs and symptoms 
Admission 
date 
Discharge 
date 
No.of days 
Treated 
 
Result 
1. 168 Jisha 3FC 3 Ulceration in right buccal mucosa, ulcer 
in tongue side border, fever, pallor 
26.01.2019 08.02.2019 14 Good 
2. 235 Shanmuga 
sundaram 
12MC 3 Ulceration in left buccal mucosa, excess 
salivation 
02.02.2019 16.02.2019 15 Good 
3. 324 Jenifer 7FC 3 Ulceration in right buccal mucosa, 
burning sensation, coated tongue. 
11.02.2019 28.02.2019 18 Good 
4. 386 Kavesh 8MC 2 Ulceration in tongue, side border, 
cervical lymphadenopathy. 
16.02.2019 02.03.2019 15 Good 
5. 547 Swetha 12FC 3 Ulceration in right buccal mucosa, 
irritation over the ulceration, cervical 
lymphadenopathy 
02.03.2019 17.03.2019 16 Good 
6. 563 Seetha parvathi 12FC 3 Ulceration in inner aspect of lips, 
irritation over the ulcer area. 
05.03.2019 23.03.2019 19 Good 
7. 668 Imran 8MC 3 Ulceration in right side buccal mucosa, 
ulcer in inner aspect of lips, excess 
salivation, pallor. 
14.03.2019 28.03.2019 15 Good 
8. 682 Selciya 6FC 2 Ulceration in inner aspect of buccal 
mucosa, fever, cervical 
lymphadenopathy 
16.03.2019 30.03.2019 15 Good 
9. 786 Abishek 3 ½ MC 3 Ulceration in left buccal mucosa, coated 
tongue, irritation over the ulcer area, 
fever, cervical lymphadenopathy, pallor 
27.03.2019 09.04.2019 14 Moderate 
10. 820 Harun 3MC 4 Ulceration in lower lip, irritation over 
the ulcer area, coated tongue., pallor 
29.03.2019 11.04.2019 14 Moderate 
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11. 821 Baby 12FC 3 Weeks  Ulceration in lower lip, excess 
salivation. Ulceration in tongue, burning 
sensation in ulcer area 
29.03.2019 11.04.2019 14 Good 
12. 830 Yaksha sri 3FC 3 Ulceration in inner aspect of buccal 
mucosa, difficulty in swallowing, 
running nose. 
30.03.2019 12.04.2019 14 Good 
13. 831 Alen Jeron 10MC 3 Ulceration in lower lip, irritation over 
the ulcer area, coated tongue, cervical 
lymphadenopathy 
30.03.2019 12.04.2019 14 Good 
14. 843 Raja 8MC 3 Ulceration in left buccal mucosa, pain in 
ulcer area, pallor 
01.04.2019 15.04.2019 15 Good 
15. 884 Mohit 
Narayanan 
8MC 3 Ulceration in lower lip, irritation over 
the ulcer area, coated tongue. 
04.04.2019 18.04.2019 15 Good 
16. 930 Rishi 7MC 3 Ulceration in side border of tongue,  
coated tongue, cervical 
lymphadenopathy 
11.04.2019 24.04.2019 14 Good 
17. 937 Raja 10MC 3 Ulceration in lower lip, pain in ulcer 
area, excess salivation 
14.04.2019 27.04.2019 14 Good 
18. 956 Kavini 4FC 3 Ulceration in lower lip, pain in ulcer 
area, fever, running nose, cervical  
lymphadenopathy 
16.04.2019 30.04.2019 15 Good 
19. 999 Rithesh 8FC 3 Ulceration in right buccal mucosa,  
irritation over the ulcer area, cervical  
lymphadenopathy 
22.04.2019 05.04.2019 14 Good 
20. 1016 Nahoor 10MC 3 Ulceration in inner aspect of buccal 
mucosa, ulcer in side border of tongue, 
pallor 
23.04.2019 06.04.2019 14 Good 
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Table  : 17  LABORATORY INVESTIGATIONS 
BT – Before Treatment,   AT -  After Treatment, P – Polymorphs,  L – Lymphocytes, E-Eosionophils,   ESR – Erythrocyte 
Sedimentation Rate, Hb - Haemoglobin A- Albumin, S – Sugar, D – Deposits,N - Nil 
S.No. IP.No Name of the patient 
Age / 
Sex 
Haematological Investigation Urine Analysis Motion Analysis 
WBC Total 
Count cells /  
cu.mm 
WBC differential count ESR – mm/ Hr Hb gm% Before Treatment After Treatment 
Before 
Treatment 
After 
Treatment 
BT AT BT AT 
A S D A S D Ova Cyst Ova Cyst 
BT AT P% L% E% P% L% E% 
½ 
hr 1hr 
½ 
hr 1hr BT AT 
1. 168 Jisha 3FC 8400 8000 61 35 4 61 36 5 12 24 8 16 9.3 9.3 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2. 235 Shanmuga 
sundaram 
12MC 
9000 9200 61 26 3 62 28 3 6 12 6 12 11.5 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3. 324 Jenifer 7FC 8600 8400 68 32 7 65 30 6 8 16 8 16 10.2 10.2 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4. 386 Kavesh 8MC 8800 8600 59 40 6 58 42 5 7 14 7 14 10.6 10.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5. 547 Swetha 12FC 8000 8200 60 30 4 58 32 4 9 18 7 14 11.0 11.0 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6. 563 Seetha parvathi 12FC 7600 7800 56 35 3 56 36 3 6 12 6 12 10.6 10.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7. 668 Imran 8MC 8200 8000 52 25 4 52 28 4 5 10 6 12 7.6 7.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8. 682 Selciya 6FC 7000 7300 64 34 7 62 32 7 6 12 5 10 9.8 9.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9. 786 Abishek 3½ 
MC 7100 7300 60 40 6 60 38 7 14 28 10 20 8.0 8.0 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10. 820 Harun 3MC 7600 7800 48 32 4 44 30 5 7 14 7 14 8.8 8.9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11. 821 Baby 12FC 9200 9000 62 33 8 60 35 8 5 10 6 12 10.2 10.3 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12. 830 Yaksha sri 3FC 8200 8600 52 40 12 52 42 8 12 24 9 18 10.8 10.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13. 831 Alen Jeron 10MC 8800 8800 54 44 6 54 42 6 8 16 8 16 10.5 10.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14. 843 Raja 8MC 7600 7800 47 42 7 47 40 7 6 12 6 12 8.2 8.3 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15. 884 Mohit 
Narayanan 
8MC 9200 9000 55 35 4 56 36 4 7 14 6 12 11.4 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16. 930 Rishi 7MC 9000 9200 62 38 3 64 38 4 8 16 7 14 11.4 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17. 937 Raja 10MC 7800 8000 48 34 4 48 32 5 6 12 6 12 10.8 10.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18. 956 Kavini 4FC 8200 8000 62 42 10 62 40 7 7 14 6 12 10.6 10.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19. 999 Rithesh 8FC 8400 8200 65 44 3 54 42 4 8 16 7 14 11.4 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20. 1016 Nahoor 10MC 9000 9200 62 30 4 60 32 5 7 14 6 12 8.8 8.9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
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Table : 18. RESLTS AFTER TREATMENT 
a. Among 20 OP cases the results were observed as follows. 
 
 
 
 
Inference: 
 80% of cases showed significant improvement.  Because  their signs and 
symptomes were reduced markedly.  They were come under good response.  About 
20% of cases showed moderate improvement. 
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1. Good  16 80 
2. Moderate 4 20 
3. Poor 0 0 
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b. Among 20 IP cases the results were observed as follows. 
 
 
 
 
Inference: 
 90% of cases showed significant improvement.  Because  their signs and 
symptomes were reduced markedly.  They were come under good response.  About 
10% of cases showed moderate improvement. 
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1. Good  18 90 
2. Moderate 2 10 
3. Poor - - 
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Table : 19. RESULTS ACCORDING TO AGE CRITERIA AFTER 
TREATMENT 
S.N
o 
Age 
Good Relief Moderate Relief Mild Relief 
Number 
of 
Cases              
(Out of 
40 ) 
Percentage 
(%) 
Number 
of 
Cases              
( Out of 
40 ) 
Percentage 
(%) 
Number 
of 
Cases            
(Out of 
40 ) 
Percentage 
(%) 
1. 3 – 7 Years 13 32.5 1 2.5 - - 
2. 7 – 12 years 21 52.5 5 12.5 - - 
  
 
 
Inference: 
 Among 40 cases, the Good Relief percentage was highest in the age group of   
7 – 12 years, the percentage was 52.5% and between the age group of 3-7 years, the 
percentage was  32.5% 
  The Moderate Relief percentage was highest in the age group of 7-12 years, 
the percentage was 12.5% and between the age group of  3- 7years, the percentage 
was 2.5%. 
  
  
32.5
2.5
0
52.5
12.5
0
0
10
20
30
40
50
60
Good Relief Moderate Relief Mild Relief
3 – 7 Years 7 – 12 years
 102
Fig. 4  
O.P. No. 108618             Name :  LAVANYA          Age :  10 Years  / FC  
Before Treatment       After Treatment 
 
 
 
 
 
 
 
 
 
 
          O.P. No. 74364              Name :  AMUTHA            Age :  12 Years  / FC  
          Before Treatment                 After Treatment 
 
 
 
 
 
 
 
 
 
 
O.P. No. 105567         Name :  THARUNRAJ     Age :  11 Years  / MC  
          Before Treatment               After Treatment 
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             I.P. No. 668                    Name :  IMRAN                 Age :  8 Years  / MC 
Before Treatment       After Treatment 
 
 
 
 
 
 
 
 
 
 
 
          I.P. No. 168                       Name :  JISHA                Age :  3 Years  / FC  
          Before Treatment                 After Treatment 
 
 
 
 
 
 
 
 
 
 
          I.P. No. 830                  Name :  YAKSHA SRI      Age :  3 Years  / FC  
          Before Treatment                After Treatment 
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10. DISCUSSION 
 Ull Akkaram is one of the disease affecting the children.  The disease ull 
Akkaram in siddha system due to excess heat production in moolam and affect the 
oral cavity to induced ulceration. 
 The symptoms of the disease ull Akkaram are, ulcer in oral cavity, coated 
tongue, fever, running nose, pallor, polydipsia, which are correlates with the aphthous 
stomatitis in modern system of medicine. 
 The symptoms of ull Akkaram were reduced & controlled by the trial 
medicine poovarasu ennai. 
Case Report 
 According to the signs and symptoms mentioned in siddha literature about 40 
cases were selected for treatment (20 OP and 20 IP). 
 Patients were treated both in out patients and In patients ward in post graduate 
Department of Kuzhanthai Maruthuvam, Government Siddha Medical and Hospital, 
Palayamkottai. 
 Out of 20 cases were admitted in-patients, and the other 20 cases were treated 
in out patient ward. 
The inferences given below 
1. Distribution according to age 
1. 65% were under the age of 7-12 years, 
2. 35% were under the age of 3-7 years. 
2. Distribution according to sex 
 52.5% were female children, 47.5% were male children. 
3. Distribution according to relegion 
 85% cases were hindu, 7.5% were christian and muslim. 
4. Distribution according to socio economic status 
 70% cases were middle, 30% were lower  class people. 
5. Distribution according to etiology 
 10% patients were affected by Trauma, infections, allergy.  50% patients  were 
affected by others (spicy foods, climate, unknown) 15% were affected by 
medications, 5% were affected by hematinic deficiency. 
6. Distribution according to diet 
 80% cases have mixed diet, and 20% have vegetarian diet. 
 105
7. Distribution according to Paruvakalam 
 32.5% were admitted in Pinpanikaalam,  
 30% were admitted in Kaarkalam, 
 20% were admitted in Munpanikaalam,  
 12.5% were admitted in Elavenilkaalam 
 5% were admitted in Koothirkaalam 
8.  Distribution according to lands 
 87.5% patients belongs to marutham nilam, and 12.5% patients belongs to 
neithal nilam. 
9. Distribution according to mode of onset 
 100% cases affected by Acute infection 
10. Distribution according to Clinical presentation 
 Ulcer in buccal mucosa present in 45% of cases,  
 Ulcer in lips 47.5% of cases,  
 Ulcer in tongue 20% of cases, 
Coated tongue 20% of cases 
 Running nose 12.5% of cases 
 Fever 15% of cases 
 Pallor 20% of cases 
Cervical lymphadenopathy 27.5% of cases. 
11. Distribution according to Tridosham 
 Uthanan 100% of cases, kirukaran 40% of cases are affected in Vatham. 
 Analpitham 100% cases, Ranjagam 50% of cases, Sathagam 50%  of cases are 
affected in pitham. 
 Kilethagam 100% cases, pothagam 40% of cases are affected in kabam. 
12. Distribution according to Ezhu udalkattugal 
 Saaram was affected in 100% cases of the patients 
 Senneer was affected in 50% of patients 
 Oon was affected in 100% of patients 
13. Distribution according to Envagai thervugal 
 On examination of Envagai thervugal 
Pitha kabam Nadi was observed in 75% of cases, Pitha vatham Nadi was 
observed in 25% of cases 
 Sparisam were affected in 15% of cases 
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 Na were affected in 40% of cases,  
 Niram were affected in 20% of cases 
 Mozhi were affected in 15% of cases 
 Vizhi were affected in 20% of cases 
14.Distribution according to Neerkuri, Neikuri 
In neerkuri, the urine of 100% patients were observed 
 In neikuri, the urine of 90% patients spreads like  ring, the urine of 5% 
patients spreads like serpent, the urine of 5% patients spreads like pearl. 
15.Distribution according to Results after treatment 
Out of 20 patiens, in OP 80% have good relief, 20% have moderate, out of 20 
patients, in IP 90% have good relief, 10% have moderate. 
Laboratory investigations 
 Most of cases were had normal TC, DC, ESR, Hb, some of cases were had 
increased WBC and increased ESR, and decreased Hb%. 
Biochemical analysis 
 The bio chemical analysis of trial medicines, showed sulphate, chloride, 
starch, ferrous iron, unsaturated compound, amino acid. 
Pharmacological analysis 
 The trial drug has significant anti inflammatory, anti pyretic activity. 
Anti microbial analysis 
 Antimicrobial study was done the trial drugs shows sensitive to 
staphylococcus aureus. 
Clinical assessment 
 In totally 40 cases, 85% cases had good prognosis, 15% had moderate 
prognosis. 
 Therefore the results were find satisfactory in all cases. 
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11. SUMMARY 
 The research study on Ull Akkaram is chosen with the patients who are 
suffering from this disease. 
 Various literatures having relevant reference to the disease, “Ull Akkaram” 
were collected from both siddha system as well as in modern system of medicine. 
 Twenty cases from both sexes of different age groups were selected and 
treated with “Poovarasu Ennai” in the out-patients and Inpatients ward of post 
graduate kuzhanthai maruthuvam Department. 
 The In-patient were treated 7 to 14 days depending upon the severity of illness 
and they were advised to attend the out-patient department for further follow up. 
 Routine laboratory investigations were done. Prognosis of the patients was 
noted. 
 The clinical diagnosis of “Ull Akkaram” were done on the basis of siddha 
aspects. 
 The clinical study were conducted in 20 out-patients 16 had good relief (80%) 
4had moderate relief (20%). 
  The clinical study were conducted in 20 In-patients 18 had good relief (90%)  
2 had moderate relief (10%). 
 The efficacy of the trial medicine were studied by Biochemical, 
microbiological study and pharmacological analysis. 
 The biochemical analysis reveals the presence of  sulphate, chloride, starch, 
ferrous iron, unsaturated compound, amino acid in the drug Poovarasu Ennai. 
 The toxicity study in “Poovarasu Ennai” reveals that there is no acute toxicity 
effects in this drug. 
 The pharmacological analysis of the drug “Poovarasu Ennai” possesses 
significant activity on anti-inflammatory and anti-pyretic action. 
 The microbiological analysis reveals resistant for pseudomonas aeruginosae, 
Escherichia coli and sensitive for staphylococcus aureus. 
 Thus the analysis ensure the efficacies of the trial medicines which were 
proved clinically. 
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12. CONCLUSION 
 
  The clinical study show that 85% of the patients were completely cured and 
also proved clinically, there was no recurrence of symptoms. 
  The trial medicines were very effective to patients and are free from adverse 
effects. 
  The drugs are not expensive and also easily available. 
 The trial medicines were very safe to the children. 
  Thus it conclude “ULL AKKARAM” is controllable and curable disease with 
“POOVARASU ENNAI” along with good personal hygiene and diet. 
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ANNEXURE – II 
CASE SHEET PROFORMA 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”  -A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
Form I-SCREENING & SELECTION PROFORMA 
S.I.No: ………….  OP/IP No: ……….  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
INCLUSION  CRETERIA:     YES      NO   
• Age 3-12 years. 
• Ulcer in oral cavity 
a. Ulcer in buccal mucosa       
b. Ulcer in lips 
c. Ulcer in tongue      
• Coated tongue 
• Fever 
• Running nose 
• Pallor 
• Polydypsia 
EXCLUSION CRITERIA: 
• Age limit :Morethan 13 years 
• Ca check 
• Ariboflavinosis 
• Secondary syphilitic ulcer 
• Herpetic gingivo stomatitis 
• Chemical burns 
• Heat burns 
 
Signature of Guide:              Signature of Principal Investigator: 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
FORM IA – HISTORY PROFORMA ON ENROLLMENT 
 
Patient id: OP/IP NO. VISIT DATE (___/____/_____) 
NAME :  
AGE:  
Gender:   MALE           FEMALE  Date Of Birth :( ____/____/_____)   
Fathers/Mother/Guardian name :  
Fathers Occupation:  
Fathers Monthly income:  
Religion:  
Socioeconomic status:  
Patient informant :  
 
 
 
 
 
 
 
 
1. Complaints and duration  
 
 
 
2. Present illness  
 
Postal Address  
 
Contact no: 
xiv 
 
 
 
History of past Illness 
History /Symptoms /Signs   Yes  No  if, Yes Details  
Any Similar Complaints      _____________ 
Bronchial Asthma       _____________ 
Dust Allergy        _____________ 
Hospitalization        _____________ 
Any Other         _____________ 
 
Family History       
Any hereditary familial Disease    Yes  No 
If yes, details………………………………………………………………………….. 
 
Immunization History  
Proper Immunization given   Yes  No …………………….. 
 
Food Habits:  
1. Veg   2. Non-Veg   3. Mixed  
 
General assessment                            Yes  No 
1. Picca 
2. Nail Biting 
3. Bowel Movements  
 
General Examination   Yes  No   
1. Pallor       
2. Jaundice        
3. Cyanosis         
4. Clubbing         
5. Pedal oedema        
6. Lymph adenopathy         
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
xv 
 
Vital signs:- 
1. Pulse rate / mint 
2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
5. BP 
 
Anthropometry: 
 Height 
Weight 
Head Circumference 
Chest Circumference 
Mid Arm Circumference 
 
CLINICAL EXAMINATION: 
             Normal            Affected 
 Cardio Vascular system:        
 Gastro intestinal system:        
 Musculo skeletal system:        
 Central nervous system:        
 Endocrine system:  
 
CLINICAL EXAMINATION OF SKIN: 
1. Site: 
………………………………………………………………………………… 
 
………………………………………………………………………………..... 
2. Colour: Normal    Reddish      Black    Pallor    
3. Itching: No                     Mild                 Moderate            Severe                   
 
EXAMINATION OF NAILS: 
1. Pallor:  Present              Absent               
2. Koilonychia: Present              Absent               
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Nilam:  
 
            Kurinji  Mullai                Marutham        Neithal         Paalai 
KaalaIyalbu 
Kaarkalam  Koothirkaalam Munpanikaalam 
Pinpanikaalam Illavenikaalam Muthuvenrkaalam 
Yaakai 
 
Vatham  VathaPitham  VathaKabam 
 
Pitham   PithaVatham  PithaKabam 
 
Kabam   KabaVatham  KabaPitham 
UyirThathukkal 
Vatham 
  Normal Affected  Remarks  
Praanan 
Abaanan 
Uthaanan 
Viyaanan 
Samaanan 
Nagaan 
Koorman 
Kirugaran 
Devathathan 
Dhanajeyan 
 
Pitham 
     Normal  Affected  Remarks  
Analagam 
Ranjagam 
Saathagam 
Alosagam 
Prasagam 
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Kabam 
     Normal   Affected  Remarks  
Avalambagam 
Kilethagam 
Pothagam 
Tharpagam 
Santhiga 
 
Udalthathukkal 
      Normal    Affected  Remarks  
Saaram 
Senneer 
Oon 
Kolupu 
Enbu 
Moolai 
Sukilam/Suronitham 
 
EnvagaiThervugal 
   Normal Affected  Remarks  
Naa 
Niram  
Mozhi  
Vizhi  
Malam 
Niram     
Nurai     
Elagal  
Erugal  
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Moothiram 
Neerkuri:  
Niram  Normal   Affected 
Edai  Normal   Affected 
Nurai  Normal   Affected 
Manam Normal   Affected 
 Enjai  Normal   Affected  
Neikuri: 
 Vatham 
 Pitham 
 Kabam 
 Others 
 
Naadi: 
ThaniNadi 
 Vadham  Pitham   Kabam 
 
ThonthaNadi 
 VathaPitham  Pithavatham PithaKabam Kabapitham 
 
Sparism 
Diagnosis__________________________________ 
Admitted to trial : 1. Yes   2. No. 
if yes, S.No:  1IP   2.OP 
 
Diagnosis 
DRUGS ISSUED:______________ 
Date :________________________ 
Station _______________________ 
Date :      
Signature of the Guide   Signature of Principal Investigator: 
 
Signature of the HOD  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
FORM-IB:CASE SHEET PROFORMA-“ULL AKKARAM” 
 
 
 
 
 
 
 
 
           
  Religion: 
       
       
       
 
 
 
 
 
 
 
     
  
I.P.No. : 
 
Bed. No. : 
 
Name of the Medical unit: 
 
Name : 
 
Age/Sex: 
 
Permanent Address: 
 
 
 
 
Temporary Address: 
PG-Pediatric Ward, Government Siddha 
Medical College & Hospital, 
Palayamkottai. 
Informant: 
 
Invesitgator: 
 
 
Nationality: 
 
Religion: 
 
Occupation(Parents): 
 
Income: 
 
Date of Admission: 
 
 
Date of  Discharge: 
 
 
Diagnosis: 
 
 
 
 
 
 
 
 
 
 
Medical Officer: 
xx 
 
Complaints and duration : 
 
 
 
History of present illness : 
 
 
 
History of past illness : 
 
 
Personal History: 
 
 
Family History: 
 
Consanguinity    : 
 Ataxia     : 
 Blindness    : 
 CP     : 
 MR     : 
 Seizure    : 
 Movement disorder   : 
 Deafness    : 
  
Socio-Economic Status: 
 
Habits: 
 Bowel and micturation habit  : 
 Sleep     : 
 Enuresis    : 
 Thumb sucking   : 
 Nail biting    : 
 Pica     : 
xxi 
 
Diet History : 
 Appetite    : 
 Types of diet    : 
 
Antenatal History : 
 Medication    : 
 Infection (STARCH)   : 
 Irradiation    : 
 Toxaemia    : 
 Hemorrhage    :  
 Severe Anaemia   : 
 Eclampsia    : 
 H/o Decreased foetal Movements : 
 Maternal malnutrition   : 
 Maternal Diabetes Mellitus(DM) : 
 Maternal Hypertension  : 
 
Natal: 
 Breech presentation   : 
 Forceps / - C- Section   : 
 Home / Hospital   : 
 H/o prolonged labour   : 
 
Post Natal 
 Post partumHaemorrhage  : 
 Sepsis     : 
 
Neonatal History: 
 Birth Weight    : 
 Term / Pre term baby   : 
 Congenital malformations  : 
 Birth Asphyxia – APGAR – Score : 
 Neonatal convulsions   : 
 Kernicterus    : 
xxii 
 
 Diarrhoea    : 
 Birth injury / Head injury / Activity of the child 
a) at birth   : 
b) after birth   : 
Time of cry after birth  : 
Resusscitation done or not  : 
(if done nature of resusscitation) 
Respiratory distress / cyanosis : 
Fever / altered sensorium  : 
Feeding after birth   : 
Lymphadenopathy   : 
 
Developmental History : 
 
 
Immunization History : 
 
 
General Examination 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
 
 
1. Consciousness : 
2. Decubitus  : 
3. Anemia   : 
4. Jaundice   : 
5. Cyanosis   : 
6. Clubbing   : 
7. Pedal oedema  : 
xxiii 
 
8. Lymphadenopathy   : 
9. Nourishment  : 
10. Skin changes   : 
11. Edema   : 
12.JVP   : 
13.Pulse Rate   : 
14.Heart Rate   : 
15.Respiratory Rate  : 
16.Temperature  : 
17.Blood Pressure  : 
18.Spine   : 
19.Skin    : 
 
Systemic Examination 
Cardio Vascular System : 
Respiratory System  : 
Gastro Intestinal System : 
Genito Urinary System : 
Nervous System  : 
 Consciousness: 
 Temper Tantrum:  Sociable- Irritable - Playful 
 Memory  : 
 Orientation  : 
 Speech   : 
 Intelligence (I.Q) : 
 Handedness  : 
 
Cranial Nerve Examination: 
Motor System: 
 Power  : 
 Tone  : 
 Reflex  : 
 Grip  : 
 Gate  : 
xxiv 
 
 
Sensory Examination: 
 Superficial Sensation: 
  Touch  : 
  Pain  : 
  Temperature : 
 Deep Sensation: 
  Position sense : 
  Joint sense : 
  Vibration sense: 
 Cortical Sensation: 
   
 
Cerebellar Signs: 
 
 
Autonomic System: 
 
Siddha Systems – Clinical Examination: 
Nilam 
Kurinchi  : 
Mullai   : 
Marutham  : 
Neithal   : 
Palai    : 
ParuvaKaalam 
Kaar   : 
Koothir  : 
Munpani  : 
Pinpani   : 
Elavenil  : 
Muthuvenil  : 
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Uyirthathukal: 
Vatham 
Praanan  : 
Abaanan : 
Uthaanan  : 
Viyaanan  : 
Samaanan : 
Naagan  : 
Koorman : 
Kirugaran  : 
Devathathan : 
Dhananjeyan  : 
 
Pitham 
Analam  : 
Ranjagam  : 
Sathagam  : 
Alosagam  : 
Prasagam  : 
 
Kabam 
Avalambagam  : 
Kilethagam   : 
Pothagam   : 
Tharpagam   : 
Santhigam   : 
UdalKattugal 
Saaram    : 
Senneer   : 
Oon     : 
Kozhuppu   : 
Enbu     : 
Moolai    : 
Sukkilam/Suronitham  : 
xxvi 
 
EnvagaiThervugal 
Naadi    : 
Sparisam   : 
Naa    : 
Niram    : 
Mozhi    : 
Vizhi    : 
Malam    : 
Moothiram   : 
Neerkuri 
Niram    : 
Manam   : 
Nurai    : 
Edai    : 
Enjal    : 
 
Neikuri 
 
 
Malakuri 
Nirami   : 
Nurai    : 
Elagal   : 
Erugal   : 
 
 
Lab Investigations 
1. Blood 
TC  : 
DC : 
Hb  : 
ESR  : 
2. Urine 
Albumin  : 
xxvii 
 
Sugar   : 
Deposits  : 
3. Motion 
Ova   : 
Cyst  : 
Occult blood  : 
DIFFERNTIAL DIAGNOSIS  : 
PROGNOSIS    : 
MARUTHUVAMURAI   : 
ADVICE     : 
DAILY PROGRESS   : 
 
Date 
 
Symptoms Medicine 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
FORM - II&IIA  
CLINICAL ASSESMENT ON ENROLLMENT DURING AND AFTER TRIAL 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: ………… 
Date of Completion :………….   Informant: …………. Reliability :  …………… 
SIDDHA SYSTEM OF EXAMINATION 
 I.ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
1.NAADI: [PULSE PERCEPTION] 
2.SPARISAM: [SENSITIVITY] 
 
3.NAA:[TONGUE]  
 
4.NIRAM: [COMPLEXION] 
 
 
 
5.MOZHI: [VOICE] 
 
 
 
6.VIZHI: [EYES] (Lower palpebral conjunctiva) 
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7.MALAM: [BOWEL HABITS / STOOLS] 
 
 1stDay 07thDay 14th Day 
Colour Dark/Yellow/ 
Red/ Pale 
Dark/Yellow/ 
Red/ Pale 
Dark/Yellow/ 
Red/ Pale 
Consistency Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Stool bulk Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
8.MOOTHIRAM[URINE EXAMINATION]: 
 
NEERKURI 1stDay 07thDay 14th Day 
Niram White/ White/ White/ 
[Colour] Yellowish/ Yellowish/ Yellowish/ 
 Straw Straw Straw 
 coloured/ Coloured/ coloured/ 
 Crystal Crystal Crystal 
 clear clear clear 
Manam[Odour] Present/ 
Absent 
Present/ Absent 
 
Present/ Absent 
 
 
 
 
 
 
 
 
 
 
 
 
Nurai[Froth] Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Edai[Sp.gravity] Normal/ 
Increased/ 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
Enjal[Deposits] Present/ 
Absent 
Present/ Absent Present/ Absent 
Volume Normal/ 
Increased/ 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
xxx 
 
 
 
 
 
 
II.THEGI: [TYPE OF BODY CONSTITUTION] 
 
III.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
Kurinji Mullai  Marutham NeithalPalai 
    (Hillyterrain)      (Forestrange)         (Plains)           (Coastalbelt)  (Aridregions) 
IV.KAALAM: 
Kaarkalam  -   Pinpanikalam   - 
Koothirkalam  -   Ilavenil  -     
Munpanikalam -   Muthuvenil  - 
V.MUKKUTRAM:[AFFECTION OF THREE HUMORS]  
A)VATHAM: 
 1stDay 07thDay 14th Day 
Praanan    
Abaanan    
Viyaanan    
Udhaanan    
Samanan    
Naagan(Higher intellectual 
function) 
   
Koorman(airway of yawning)    
Kirukaran(Air of 
salivation/nasal  secrection) 
   
Devathathan (Air of laziness)    
Dhananjeyan(this air that acts 
on death) 
   
 
 
NEIKURI 1stDay 07thDay 14th Day 
Serpentine fashion    
Annular/Ringed  fashion    
Pearl beaded fashion    
Mixed fashion    
 
xxxi 
 
B.PITHAM: 
 
 1stDay 07thDay 14th Day 
Analpitham (Gastric 
juice) 
   
Ranjagam(Haemoglobin)    
Saathagam(Life energy)    
Praasagam (Bile)    
Aalosagam    
 
C.KABAM: 
  
 1stDay 07thDay 14th Day 
Avalambagam (Serum)    
Kilaethagam (saliva)    
Pothagam (lymph)    
Tharpagam(cerebrospinal 
fluid) 
   
Santhigam(synovialfluid)    
 
VI.SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 1stDay 07thDay 14th Day 
Saaram [Chyme]    
Senneer [Blood]    
Oon [Muscle]    
Kozhuppu [Fat]    
Enbu [Bones]    
Moolai [Bonemarrow]    
Sronitham[Genital  discharges]    
 
xxxii 
 
 1.SYSTEMIC EXAMINATION: 
 
 1stDay 07thDay 14th Day 
1)Gastrointestinal  System    
2) Respiratory System    
3)Cardiovascular  System    
4)Central Nervous System    
5)Urogenital System    
 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
 
 
2. GENERAL EXAMINATION: 
 
 
 1stDay 03thDay 7th Day 11
th Day 14th Day 
Height (cms)      
Weight (kg)      
Temperature (F0)      
Pulse rate (per min)      
Heart rate (per min)      
Respiratory rate(per min)     
Blood pressure (mm/Hg)      
Anaemia      
Jaundice      
Cyanosis      
Lymph adenopathy      
Pedal edema      
Clubbing      
Jugular vein pulsation      
xxxiii 
 
 
3.CLINICAL SYMPTOMS: 
 
COMPLAINTS 1st day 7th day 14th day 
Ulcer in oral cavity    
a. Ulcer in buccal mucosa    
b.  Ulcer in lips    
c.  Ulcer in tongue    
Coated tongue    
Running nose    
Fever    
Pallor    
Polydipsia    
Cervical lymphadenopathy    
 
   
Date: 
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide : 
 
 
    
        Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
S.I.No: ………….  OP/IP No: …………  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
 
FORM III – LABORATORY INVESTIGATION 
 
Routine blood investigations Normal 
values 
Before TMT 
date: 
After TMT 
date: 
Hb (gms%)    11.5- 14.5   
T.RBC (milli/cu.mm) 4-4.9   
ESR(mm) ½ hr. 0-4   
1hr. 0-13   
T.RBC (milli/cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
 
 
Urine Investigation Before TMT  
Date : 
After TMT  
Date : 
Albumin   
Sugar   
Deposits   
 
xxxv 
 
 
Stools Investigation Before TMT  
Date : 
After TMT  
Date : 
OVA   
Cyst   
Occult blood   
 
 
 
Date : 
 
 
 
Signature of Guide:    Signature of Principal Investigator:
  
 
 
 
Signature of HOD:  
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
 
       CONSENT FORM 
 
An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation“POOVARASU ENNAI” for the management “ULL AKKARAM” 
 
CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….      Signature………….. 
place ……………….     Name ……………… 
 
CONSENT OF INFORMANT 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up including 
the laboratory investigations to be performed to monitor and safeguardmy Son / 
Daughter body functions. 
I am aware of my right to opt out of the trial at any time during the 
courseofthe trial without having to give the reasons for doing so. 
I am, exercising my free power of choice; hereby give my consent to be 
included as a subject in the clinical trial of “POOVARASU ENNAI”for the 
treatment of “ULL AKKARAM” 
Informant Signature:………. 
Date:        Informant Name: …………. 
Place:        Patient Name:………………. 
Signature of Witness     Relationship:………………… 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
FORM IVB – WITHDRAWAL 
 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 
Pt. not willing to continue  : Yes /No 
Date : 
 
 
Signature of Guide:    Signature of Principal Investigator:
  
 
 
Signature of HOD:  
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FORM IV-C – PATIENT INFORMATION SHEET 
Name of the principal investigator: 
……………………………………………………. 
Name of the institution  :  GOVERNMENT SIDDHA MEDICAL  
         COLLEGE&HOSPITAL, 
 Palayamkottai 
Information sheet for patients participating in the open clinical, trial  
 
1, ____________________________ Studying as PG Scholar at  GOVERNMENT 
SIDDHA MEDICAL COLLEGE & HOSPITAL, PALAYAMKOTTAI  is doing 
a trail on the study “ULL AKKARAM”. It  is a most common  disease in children. In 
this regard, I am in a need to ask you few questions. I will maintain confidentially of 
your comments and data obtained. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this 
study. Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study.  
You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions.  
If you agree your child to be a participate in this study, he/she will be included 
in the study primarily by signing the concern form and then you will be given the 
internal medicine “POOVARASU ENNAI for 14 days 
 
Date : 
 
 
Signature of Guide:              Signature of Principal Investigator: 
 
 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
FORM IVD- DIETARY ADVICE FORM 
 
S.I.No: ………….    OP/IP No: …………  Name: ……………… 
Age: ……………. Gender:  …………..   Date of Enrollment: …… 
Date of Completion :……… Informant: …………. Reliability :  …………… 
 
The following diet to be taken: The following food should be avoided 
• givlqz<zik!d{U!
• hiz<?!ou{<o{b<?!!
• Ljzg<gm<cb!kieqbl<?!
hbqX!
• gQjvgt<!
• ofb<!Osi<f<k!d{U 
• Htqh<H?!giIh<H!d{U!
• $mie!d{U!
• Carbonated drinks!
!
!
!
 
 
 
Date: 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide : 
    
        Signature of the HOD 
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1. Patient /Consumer Identification (Please complete or tick boxes below as 
appropriate) 
 
Form – IVE 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting Form For Suspected Adverse Reactions to Siddha Drugs 
 
Please Note: i. All Consumers/Patients and reporters information will remain  
          confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
                            even if it does not have complete data, as soon as possible.  
 
Peripheral centrecode :      State : 
 
Name  
 
 
Father Name  
 
Patient record no 
Ethnicity  
 
Occupation  
Address 
 
Village/Town 
Post/Via 
District /State 
Date of Birth/Age 
Sex:      Male /Female 
Weight: 
Degam: 
 
2. Description of the suspected adverse reactions please complete boxes below 
Date and time of initial 
observation  
 
 
 Season: 
xliii 
 
Description of reaction  
 
 
 Geographical area: 
 
3. List of all medicines/Formulations including drugs of other systems used by 
the patient during the reporting period:  
Medicine 
Daily 
dose 
Route of 
administration  
Vehicle – 
Adjuvant 
Date 
Diagnosis for which 
medicine taken Starting Stopped 
Siddha  
 
 
     
Any other 
system of 
medicines  
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
1) 
Details Drug  
a) Name of the Medicine   
b) Manufacturing unit and 
batch no. and date 
 
c) Expiry date  
d) Purchased and 
obtained from 
 
e) Composition of the 
formulation / part of 
the drug used 
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2) Dietary restrictions if any 
3) Whether the drug is consumed under institutionally qualified medical 
     supervision or used as self medication 
4) Any other relevant information  
5. Treatment provided for adverse reaction: 
 
 
6. The result of the adverse reaction /side effect / untoward effects ( Please 
complete the boxes below )  
Recovered Not 
recovered: 
 
Unknown Fatal If fatal 
Date of death: 
Severe Yes /No Reaction abated after drug stopped or dose reduced 
 
Reaction reappeared after re introduction : 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital  
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes 
specify: 
 
8. Whether the patient is suffering with any chronic disorders? 
 
Hepatic    Renal  Cardiac Diabetes
 Malnutrition  
Any Others  
 
9. H/O previous allergies /Drug reactions: 
 
10. Other illness (please describe): 
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Type (please tick):Nurse/Doctor/Pharmacist/Health 
worker/Patient/Attendant/Manufacturer/Distribution /Supplier /Any other    
(please Specify) 
 
 
 
Name : 
 
Address: 
 
Telephone /E-mail if any: 
 
 
 
 
Signature of the reporter      Date : 
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Please send the completed from to  
 
From 
 
Government Siddha Medical 
College &Hospital, 
Palayamkottai, Post Graduate 
Department of Kuzhanthai 
Maruthuvam 
 
 
This Filled- in ADR report may be send within one month of observation / 
occurrence of ADR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date : 
 
Station: 
 
Signature of Investigator: 
 
Signature of Guide:     Signature of HOD  
 
To, 
 The co-ordinator, 
Pharmacovigilance 
Department, 
Govt., Siddha Medical College 
and Hospital, 
Palayamkottai,  Tirunelveli. 
Who can report?  
 Any health care professionals like Siddha Doctors 
/Nurses /Siddha Pharmacists /Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence 
and protected to the fullest extent 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
Form IVF -ADMISSION – DISCHARGE SHEET 
Name of the medical unit  :    Nationality  : 
I.P.No     :     Religion  : 
Bed No    :    Informant  : 
Name     :    Date of Admission : 
Age/Sex    :    Date of Discharge : 
Occupation(parents)   :    No. of days treated  : 
Income(parents)   :    Diagnosis  : 
S.No Clinical Features 
During 
admission 
During 
discharge 
1 Ulcer in oral cavity   
 
a. Ulcer in buccal mucosa
  
 
b.  Ulcer in lips 
  
 
c.  Ulcer in tongue 
  
2 Coated tongue   
3 Running nose   
4 Fever   
5 Pallor   
6 Polydipsia   
7 Cervical 
lymphadenopathy 
  
Place: 
Date:            
           
      Signature of the Medical Officer 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “ULL AKKARAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS  POOVARASU ENNAI 
 
FORM V-DRUG COMPLIANCE  
 
S.I.No: ………….  OP/IP No: ………… Name: ……………… 
Age: …………….  Gender: …………..  Date of Enrollment: …………. 
Date of Completion :…………. Informant:………..   Reliability :  …………… 
 
NAME OF THE DRUG   : POOVARASU ENNAI 
ADMINISTRATION &ADJUVANT : PER ORAL  
DOSE & DURATION    :  3 – 7  Years  -  2 ml for 14 days  
         7 – 12 Years  - 4ml for 14 days 
NO OF DRUG PACKS GIVEN   : ________________ 
NO OF DRUG PACKS  RETURNED : ________________ 
DAY 
DATE OF DRUG 
INTAKE 
MORNING EVENING 
DAY 1    
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
DAY 8    
DAY 9    
DAY 10    
DAY 11    
DAY 12    
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DAY 13    
DAY14    
 
Date :                                                       Signature of Principal Investigator:  
 
Signature of the Guide: 
 
Signature of  HOD :  
